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1. Introduction
1.1. MCP-1
MCP-1 is a glycoprotein of 76 amino acids that was isolated and identified for the
first time from human tumor cell lines as related factor with monocyte
chemotactic activity (Van Damme, Decock et al. 1989) (Fig. 1).
It belongs to chemokines (chemotactic cytokines), a family of low-molecular-
weight (8-10 kD) proteins with four conserved cysteins. Chemokines are divided
into two subfamilies, called C-X-C and C-C chemokines, depending on whether
the two cysteins nearest the N-terminals are separated by one amino acid or not
(Miller and Krangel 1992; Baggiolino, Dewald et al. 1994). Recently, two others
subfamilies have been identified: the C chemokines, which lack the first and
third of the conserved cysteine, and transmembrane chemokines with an active
C-X-3C motif. (Bazan, Bacon et al. 1997). Most C-X-C chemokines specifically
attract neutrophils, whereas most C-C attract monocytes, T lymphocytes and in
less degree eosinophils and basophils. MCP-1 belongs to the C-C group together
with regulated on activation, normal T cell expressed and secreted (RANTES),
 macrophage inflammatory proteins-1α/1β (MIP-1α/1β), MCP-2 and MCP-3.
Members of C-X-C group are interleukin (IL)-1, IL-8. Lymphotactic is a member
of C chemokines.
The biological effects of MCP-1 and all members of the subfamilies are mediated
by the interaction with members of the superfamily of seven transmembrane
domain G protein-coupled receptors.
All members of the chemokine subfamily share the ability to induce directional
migration, growth and possible activation of specific leukocytes (Baggiolino,
Dewald et al. 1994). In vitro, MCP-1 is chemoattractant and activating for
monocytes, T lymphocytes (Jiang, Beller et al. 1992; Lukacs, Chensue et al. 1997;
Carr, Roth et al. 1994), and natural killer cells (Taub, Sayers et al. 1995). The in
vivo data are obtained using local injection of MCP-1 in different animal models
or by transgenic mice generation overexpressing MCP-1 in a variety of organs.
Experiments using intradermal injection of human MCP-1 showed monocyte
infiltration at the site of injection in rats (Zachariae, Anderson et al. 1990), and
rabbit (Van Damme, Proost et al. 1992). In contrast, intradermal injection of pure
murine MCP-1 did not induce infiltrates in mouse skin (Ernst, Zhang et al. 1994).
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Fig. 1. (A) The dimeric crystalline form of human MCP-1 as derived from X-
ray-spectroscopy (1 dok.pdb, 1.85 Å resolution). (B) The possible structure of
mouse MCP-1 (yellow) as obteined by homology modeling using
Composer/Biopolymer (Tripos force field, Kollman charges, ε= 4) with 1
dok.B.pdb as template (cyan). The quaternary structure of MCP-1 is established
for human MCP-1. Murine MCP-1 differs from human mainly by its molecular
weight with additional 49 amino acids at the C-terminus with O-linked
oligosaccharide chains terminated by sialic acid. The molecular weight of the
monomer (mouse) is approximately 25 kDa. If one considers residues 1 to 71 the
sequence identity between human and mouse MCP-1 is 59% leading to the
homologous structure of mouse MCP-1.
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Rutledge et al. using transgenic mice that constitutively express MCP-1 in a
variety of organs could not show any monocyte infiltrates in MCP-1-expressing
organs in any animals and at any age (Rutledge, Rayburn et al. 1995).
Transgenic mice, expressing human MCP-1 in type II alveolar epithelial cells
showed accumulation of monocytes and lymphocytes into the bronchoalveolar
space (Gunn, Nelken et al. 1997). In this animal model, MCP-1 alone did not
induce inflammatory activation of cells but it led to an enhanced inflammatory
response by treatment with other stimuli (Gunn, Nelken et al. 1997). Transgenic
mice overexpressing MCP-1 in the thymus and brain showed modest infiltrates of
monocytes but not lymphocytes and pronunced mononuclear infiltrates,
respectively (Fuentes, Durham et al. 1995). Transgenic mice, overexpressing
MCP-1 specifically in the heart, exhibit in young animals (from neonatal to 2
months old) focal accumulation of macrophages but not lymphocytes in the
myocardial interstitium (Kolattukudy, Quach et al. 1998). In addition, no sign of
leukocyte activation was detected at this early age (Kolattukudy, Quach et al.
1998), but MCP-1 overexpression leads in old animals to ischemic
cardiomyopathy and a gradual loss of myocytes (Kolattukudy, Quach et al. 1998;
Moldovan, Goldschmidt-Clermont et al. 2001). MCP-1-deficient mice were also
generated by targeted gene disruption (Lu, Rutledge et al. 1998). The animals
develop normally, show normal hamatologic profiles, and have normal number of
resident macrophages but they develop serious abnormalities in several
inflammatory and immunological models. Upregulation of MCP-1 mRNA has
been shown to be responsible for leukocyte recruitment following
ischemia/reperfusion of the liver in rats (Yamaguchi, Matsumura et al. 1998).
At the mRNA and protein level, MCP-1 is expressed by a variety of cells such as
monocytes, macrophages, fibroblasts, chondrocytes, keratinocytes, melanocytes,
mesangial cells, osteoblasts, astrocytes, lipocytes, mesothelial cells, epithelial
cells, endothelial cells, smooth muscle cells, and some tumor cell lines (for review
see Proost, Wuyts et al. 1996).
MCP-1 can be produced constitutively in many different tumor cells (Graves,
Jiang et al. 1989) or in normal cells after stimulation with cytokines such as IL-6,
tumor necrosis factor−α (TNF-α), interferon-γ (IFN-γ), granulocyte-macrophage
colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-
CSF), or mitogens, viruses, and endotoxins. In addition, lipopolysaccharide (LPS),
low-density lipoprotein, thrombin and shear stress can induce MCP-1 expression
by endothelial cells (Proost, Wuyts et al. 1996). Unstimulated and non-malignant
cells express low levels of MCP-1.
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MCP-1 is upregulated at mRNA and protein levels in several diseases, in which
an inflammatory response occurs, e.g., cancers, rheumatoid arthritis,
atherosclerosis, inflammatory skin diseases (psoriasis, lichenoid dermatitis,
spongiotic dermatitis), bronchial infections (idiopathic pulmonary fibrosis,
spongiotic dermatitis), liver diseases (chronic acute hepatitis, fulminant hepatic
failure), ischemia and ischemia/reperfusion injuries (Koch, Kunkel et al. 1994;
Strieter, Koch et al. 1994; Yla-Herttuala, Lipton et al. 1991; Birdsall, Green et al.
1997; Kumar, Ballantyne et al. 1997; Kakio, Matsumori et al. 2000). In ischemia
and ischemia/reperfusion injuries recruitment of leukocytes is a crucial step in
the physiological response of the infarcted tissue. During reperfusion, leukocytes
infiltrate and accumulate in the infarcted area and upon activation they initiate
the inflammatory process. The main role of MCP-1 expression during myocardial
ischemia has been attributed to its chemoattractant capacity for monocytes,
leading to the initiation of the healing process after ischemic myocardial injury.
It has been shown that MCP-1 mRNA is induced in the endothelium of small
veins in the ischemic area within the first hour of reperfusion and peaked at 3
hours (Kumar, Ballantyne et al. 1997; Kakio, Matsumori et al. 2000), while MCP-
1 expression starts after 3 hours coinciding with the infiltration of leukocytes
(Birdsall, Green et al. 1997). Neutralization of MCP-1 significantly reduces
myocardial reperfusion injury in a rat model of ischemia/reperfusion (Ono,
Matsumori et al. 1999). MCP-1 expression has also been shown in focal cerebral
ischemia after middle cerebral artery occlusion in mouse (Che, Ye et al. 2001)
and rat (Yamagami, Tamura et al. 1999).
1.2. Mitogen-activated protein kinases
The mitogen-activated protein kinases (MAPKs) are a superfamily of Pro-
directed Ser/Thr cytoplasmic protein kinases involved in the signal transduction
pathway from extracellular stimuli to the nucleus (Lufen and Michael 2001) (Fig.
2). MAPKs respond to chemical and physical stresses through plasma membrane
or cytoplasmic receptors (such as G-protein-receptors, tyrosin kinase-receptors)
thereby controlling cell death, cell survival and adaptation. The activation of
these receptors from extracellular stimuli induces the activation of a signaling
cascade with final translocation of a terminal kinase to the nucleus, where target
proteins are modified by phosphorylation to regulate gene expressions and other
cell functions. Each kinase is activated through multistep protein kinase
cascades by dual phosphorylation on a tyrosine and a threonin residue (Fig. 2).
The cascades are composed by a MAPK, MAPK kinase (MAPKK, MKK, or MEK)
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and a MAPKK kinase or MEK kinase (MAPKKK or MEKK) (English, Pearson et
al. 1999).
MAPKKKs, MEKKs MAPKK kinase
MAPKKs, MKKs, MEKs MAPK kinase
MAPKs MAP kinase
Each MAPKs is activated by specific MAPKKs. However, they can be activated
by more than one MAPKKs, increasing the complexity and diversity of MAPKs
signalling. In general, there is a considerable specificity in MAPKs activation
(Fig. 2).
Downstream effectors of the MAPKs pathway include the so-called transcription
factors. Phosphorylation of transcription factors is the trigger for transactivation.
The transactivation is the process by which genes are activated by means of a
trans-activating domain that is contained in a transcription factor. This domain
enables transcription factors to interact with proteins that are involved in
binding RNA polymerase to DNA in a sequence-specific manner that are
favorable to the initiation of transcription. The genes that are induced by
transcription factors are called immediate-early gene for their capacity to be
induced rapidly and transiently without a need for new protein synthesis. Many
immediate-early genes control the transcription of other genes.
Transcription factors such as c-Jun, related-to-serum-response factor (RSRF),
myocyte enhancer factor 2 (MEF2), and activating transcrption factor-1/2 (ATF-
1/2), control jun family (c-jun, junB, and junD) gene expression.  Transcription
factors such as activator protein-1 (AP-1), ternary complex element (TCF), Elk-1,
serum related factor (SRF), nuclear factor-kB (NF-kB), Janus kinase/signal
transducer and activator of transcription (JAK/STAT) system, and cAMP-
response-element-binding protein (CREB) induce fos family (c-fos, fosB), Egr-1,
gadd45 β, and xiap gene expression (Kyriakis and Avruch 1996; Hazzalin and
Mahadevan 2002; Force, Pombo et al. 1996 ; Kyriakis and Avruch 2001).
 The MAPKs include different protein kinase subfamilies: the extracellular
signal-regulated protein kinases1/2 (ERK1/2 or p44 and p42 MAP kinase), 10 or
more splice variants of the stress-activated protein kinases/c-Jun-NH2-terminal
protein kinases (SAPK/JNKs), 4 isoform of p38-MAPkinases (p38-MAPKs)
designated α, β, γ and δ, 3 forms of ERK3, ERK4, ERK5, and ERK7.
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MAPKs are activated by different stimuli (Fig. 2). The ERKs are mostly activated
by growth factors such as fibroblast growth factor (FGF), insulin growth factor
(IGF), epidermal growth factor (EGF), angiotensin-II (Ang-II), and endothelin-1
(ET-1) (Fisher, Singh et al. 1998; Htun, Barancik et al. 1998). SAPK/JNKs and
p38-MAPKs are activated by cellular stress such as heat shock, ultraviolet
radiation, protein synthesis inhibitors, osmolarity changes, okadaic acid,
antibiotics, ischemia, ischemia/reperfusion, pro-inflammatory cytokines such as
TNF-α and IL-1 and to a lesser degree by growth factors (Moriguchi, Kawasaki et
al. 1995; Clerk, Harrison et al. 1999; Winston, Chan et al. 1997).
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MEK1/2/5
ERK1/2/5
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MEKK1/2/3/4
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p38α,β,γ,δ
CELL PROLIFERATION CELL SERVIVAL APOPTOSIS
CELL MOTILITY
GENE EXPRESSION
extracellular
cytosol
nucleus
GROWTH FACTORS
(FGFa/b, IGFI/II, EGF, PDGF)
CELLULAR STRESS
ISCHEMIA/REPERFUSION
PRO INFLAMMATORY CYTOKINES 
(TNF-α, IL-6)
Mos
PKCsMEKKs
MEKs
MAPKs
DIFFERENTIATION
Fig. 2. MAPKs SIGNAL TRANSDUCTION PATHWAY
The activation of ERK1/2/5 pathways is associated with the onset of survival, cell
proliferation, transformation, cell cycle control, DNA synthesis, differentiation,
long-term potentiation in neurons, the production of insulin in pancreatic β cells
(Fig. 2). ERK1/2 may also induce growth factors production (Lewis, Shapiro et al.
1998; Cobb 1999; Kato, Tapping et al. 1998; Chang and Karin 2001). ERK7
function has been associated with a negative regulation of growth (Abe, Kuo et al.
1999). The activation of ERK1/2 pathway leads to phosphorylation (activation) of
transcription factors such as Elk-1, serum response factor (S) accessory protein
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(SAP-1), MAPK interacting protein kinase-1/2 (Mnk-1/2), mitogen-and stress-
activated protein kinase (MSK1), and MAPK-activated protein kinase 1
(MAPKAP-K1), NF-kB, JAK/STAT system (Treisman 1996; Hazzalin and
Mahadevan 2002; Chakraborti and Chakraborti 1998; Chang and Karin 2001;
review in Brivanlou and Darnell 2002). ERK5 ‘s substrates is MEF 2 (Hazzalin
and Mahadevan 2002).
SAPK/JNKs and p38-MAPKs activation has been demonstrated to be involved in
apoptosis, cell transformation, proliferation, differentiation, cytokine
biosynthesis, and stress responses (Kyriakis 2001; Dong, Yang et al. 1998;
Craxton, Shu et al. 1998) (Fig. 2). Recently, activation of SAPK/JNKs pathway
has been associated with the induction of cell survival in different cell types and
animal models (Yue, Ma et al. 1998; Barancik, Htun et al. 1999; Andreka, Zang
et al. 2001). The activation of SAPK/JNKs pathway induce the phosphorylation
(activation) of transcription factors such as c-Jun, ATF-2, Elk-1, NF-kB,
JAK/STAT system (Treisman 1996; Chakraborti and Chakraborti 1998; Chang
and Karin 2001; Brivanlou and Darnell 2002; review in Hazzalin and Mahadevan
2002). p38 activates the transcription factors ATF-2, Elk-1, SRF accessory
protein (SAP-1), C/EBP homologous protein (CHOP), MEF-2, Mnk 1/2, MSK1,
and p38-related/activated protein kinase (PRAK) (Treisman 1996; Chakraborti
and Chakraborti 1998; Chang and Karin 2001; Brivanlou and Darnell 2002;
review in Hazzalin and Mahadevan 2002). In general, with the exception of
transcription factors, the MAPKs substrates that regulate processes initiated by
extracellular stimuli are not known and their identification is under study.
1.3. Ischemic preconditioning
Ischemic preconditioning is the endogenous mechanism of the myocardium to
protect itself against infarction. Ischemic preconditioning consists of short
transient periods (~5) of sublethal ischemia (5 min) and reperfusion (5 min) that
confer myocardial adaptation and resistance against cardiomyocyte death after a
subsequent prolonged coronary occlusion (Murry, Jennings et al. 1986; Cohen
and Downey 1995; Yellon, Baxter 1998). This phenomenon of marked limitation
of infarction was described for the first time in 1986 (Murry, Jennings et al. 1986)
and has been already demonstrated in every animal species studied (Yellon,
Baxter et al. 1998). The cardioprotection is only induced when the duration of
prolonged ischemia insult is 30 to 90 min, but is ineffective when this period is
more than 3 hours and the protection is only observed when the prolongated
ischemia is followed by reperfusion (Murry, Jennings et al. 1986; Yellon, Baxter
- 8 - 1. Introduction
et al. 1998). This immediate adaptation represents an early phase of protection
and is defined “classical preconditioning” (or “early preconditioning”). Secondary,
a late (or delayed) phase of ischemic preconditioning has been described and
called “delayed preconditioning” (or “second window of protection”). The “delayed
preconditioning” begins 12 to 24 hours after the stimulus and lasts 3 to 4 days
(Kuzuya, Hoshida et al. 1993; Marber, Latchman et al. 1993). It has been shown
to protect the myocardium not only from lethal ischemia/reperfusion injury (as
early preconditioning), but at least also from postischemic disfunction (Bolli 1996;
Sun, Tang et al. 1995), and arrhythmias (Kaszala, Vegh et al. 1996).
The mechanism of protection achieved by classical preconditioning is composed of
a cellular cascade and starts with adenosine and reactive oxygen species released
by ischemic myocardium, which act as triggers. Reactive oxygen species are
highly unstable molecules, capable of attacking cell membranes and subcellular
structures to induce metabolic and structural changes, that can be detrimental to
cell survival (Kukreja and Hess 1992). They include superoxide anion, hydrogen
peroxide, and hydroxyl radical, which are abundantly produced during
reperfusion (Kukreja and Hess 1992). The adenosine and reactive oxygen species
mediate the activation (phosphorylation) of protein kinase C (PKC) and ATP-
dependent K+ (KATP) channels. PKC has been described as integral and
essential intermediate intracellular messenger in the cardioprotection program
(Ytrehus, Liu et al. 1994; Speechly-Dick, Grover et al. 1995). In fact, the
inhibition of PKC activation has been shown to abolish ischemic preconditioning
in both, rabbit hearts and isolated cardiomyocytes (Ytrehus, Liu et al. 1994;
Armstrong, Downey et al. 1994). Slight oxidative modification of the regulatory
domain of PKC predisposes the protein to being easily activated (Gopalakrishna
and Anderson 1989). In addition, when PKC is exposed to oxidative stress, it is
translocated from the cytoplasm to the cell membrane, where the protein can be
easily activated (Von Ruecker, Han-Jeon et al. 1989). PKC down stream signaling
cascades include MAPKs and transcription factor activation (see below). KATP
channels have been also described as end-effector of protection in the
preconditioning program (Gross and Auchampach 1992; Yao, Mizumura et al.
1997). KATP channel blockers reverse the beneficial effects of ischemic
preconditioning (Toombs, Moore et al. 1993; Gross and Auchampach 1992). The
link between adenosine and reactive oxygen species and KATP channel
activation has also been already established. In fact, KATP channels are opened
by various species of oxigen radicals (Jabr and Cole 1993; Tokube, Kiyosue et al.
1994). Liang (Liang 1996) demonstrated a direct preconditioning of ventricular
myocytes involving adenosine-receptors (A1) and KATP channels. Although many
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studies have hypothesized that KATP channels are potential end-effector of
protection, new evidences are emerging regarding the role of the opening of these
channels in the triggering of ischemic preconditioning rather than in the end-
effecting (Pain, Yang et al. 2000; Downey and Cohen 2000). In fact, it has been
proposed that the opening of the KATP channels during ischemic preconditioning
generates free radicals that lead to a preconditioned state and activation of
MAPKs (Pain, Yang et al. 2000).
As mentioned above, delayed preconditioning becomes apparent 12 to 24 hours
after the preconditioning stimulus and lasts 3 to 4 days (Kuzuya, Hoshida et al.
1993; Marber, Latchman et al. 1993). Although early ischemic preconditioning
requires only activation of preexisting proteins, late ischemic preconditioning
needs increased synthesis of new cardioprotective proteins (Rizvi, Tang et al.
1999). A wide variety of stimuli can activate the late ischemic preconditioning,
and they can be classified as nonpharmacological and pharmacological. Initiators
(or triggers) of the late ischemic preconditioning discovered until now are
adenosine (Dana, Baxter et al. 1998), nitric oxide (Qiu, Rizvi et al. 1997), reactive
oxygen species (Sun, Tang et al. 1996), and may be opioid receptor agonists
(Fryer, Hsu et al. 1999). Mediators (or effectors) of the protection
(cardioprotection proteins) include nitric oxide synthase (in the late ischemic
preconditioning nitric oxide plays a role as a trigger as well as effector) (Bolli,
Dawn et al. 1998), cycloxygenasa-2 (Shinmura, Tang et al. 2000), aldose
reductase (Srivastana, Chandra et al. 1998), antioxidant enzymes (Hoshida,
Kuzuya et al. 1993), heat shock proteins (Radford, Fina et al. 1996), and perhaps
KATP channels (Takano, Tang et al. 2000). The cellular pathway of late ischemic
preconditioning includes activation of signaling cascade through PKC (Ping,
Takano et al. 1999), and Src protein tyrosin kinases (Imagawa, Baxter et al.
1997) leading to transcription factors activation, as NF-kB, (Xuan, Tang et al.
1999) that control the expression of the cardioprotective genes responsible for
late ischemic preconditioning (Fig. 2).
Currently, the search for the identification of the underlying intracellular
signaling pathways and endogenous or pharmacological substances able to
protect the myocardium against infarction, is one of the most important
challenges in cardiovascular research.
1.4. Ischemic preconditioning and MAPKs
It is already known that the ERKs pathway is activated during ischemia and
reperfusion (Htun, Barancik et al. 1998; Ping, Zhang et al. 1999), and that
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activation leads to protect the myocytes against cell death (Henaff, Hatem et al.
2000; Yue, Wang et al. 2000; Strohm, Barancik et al. 2000).
Ischemia and reperfusion activate the p38-MAPKs pathway, and this activation
has been associated with the induction of apoptosis or cell injuries (Bogoyevitch,
Gillespie-Brown et al. 1996; Gu, Jiang et al. 2000; Ozawa, Shioda et al. 1999).
The SAPK/JNKs pathway is activated during ischemia and is maintained during
reperfusion (Bogoyevitch, Gillespie-Brown et al. 1996; Yue, Wang et al. 2000; Gu,
Jiang et al. 2000). However, the activation of SAPK/JNKs pathway during
ischemia and reperfusion has been associated with the induction of both,
apoptosis or cytoprotection in different cell types (Ozawa, Shioda et al. 1999; Yue,
Ma et al. 1998; He, Li et al. 1999; Yue, Wang et al. 2000; Mielke, Damm et al.
2000).
Recently, several groups have shown that different members of the MAPKs
superfamily are activated during ischemic preconditioning suggesting their role
in the protection achieved by ischemic preconditioning (Weinbrenner, Liu et al.
1997; Barancik, Htun et al. 1999; Nakano, Baines et al. 2000; Sato, Cordis et al.
2000). Several studies have shown activation of the MAPKs pathways after a
preconditioning procedure and infarct size reduction by ischemic preconditioning
(Maulik, Watanabe et al. 1996; Maulik, Yoshida et al. 1998; Weinbrenner, Liu et
al. 1997). However, the precise role of each member of the MAPKs superfamily in
the induction of cardioprotection during ischemic preconditioning is still
controversial. After ischemic preconditioning, the activity of ERKs (Ping, Zhang
et al. 1999b), SAPK/JNKs (Ping, Zhang et al. 1999a), and p38-MAPKs (Nakano,
Baines et al. 2000) increase in rabbit and rat (Sato, Cordis et al. 2000). In
general, activation of ERKs pathway during ischemic preconditioning is
associated with the cytoprotection against necrosis or apoptosis (Henaff, Hatem
et al. 2000; Yue, Wang et al. 2000; Strohm, Barancik et al. 2000). In fact, specific
inhibition of ERKs pathway by PD98059 and UO126 abolishes ischemic
preconditioning-induced cardiac protection in pig myocardium (Strohm, Barancik
et al. 2000). The activation of the p38 pathway has been associated with the
induction of apoptosis or cell injury (Bogoyevitch, Gillespie-Brown et al. 1996;
Ozawa, Shioda et al. 1999). The activation of the SAPK/JNKs pathway was
originally associated with the induction of cell death (He, Li et al. 1999; Lin,
Weinberg et al. 2000; Yue, Ma et al. 1998) but recently, a cardioprotective role of
SAPK/JNKs in different organs and animal model has been reported (Sato,
Cordis et al. 2000; Barancik, Htun et al. 1999; Baines, Cohen et al. 1999; He, Li
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et al. 1999; Lin, Weinberg et al. 2000; Yue, Ma et al. 1998; Andreka, Zang et al.
2001).
1.5. TNF-α
Cytokines have a broad and overlapping range of cell regulatory activity.
Cytokines binding with cellular membrane receptors activates different
intracellular cascade of transduction signals, thereby altering the cell's pattern of
gene expression and leading to different biological effects such as cell growth,
proliferation, differentiation, migration, and cell survival or death. Different
members of the cytokine family are also important mediators of the immune
system and have critical functions in regulating immune responses.
TNF-α is a multifunctional cytokine (trimeric polypeptide) of 157 aminoacids. It
was discovered as an anti-tumor agent, when cancer patients who have a severe
infection sometimes had a regression of their tumor (Nauts 1989).  It is produced
as a 26 kD integral transmembrane precursor protein from which a 17 kD
mature TNF-α protein is released after proteolytic cleavage (Kriegler, Perez et al.
1988) catalyzed by a metalloproteinase called TNF-converting enzyme (Moss, Jin
et al. 1997). The active form exists in soluble or membrane-bound form (Decoster,
Vanhaesebroeck et al. 1995). Membrane insertion may be an effective way to
keep the action of TNF-α restricted to specific locations.
TNF-α is mainly produced by activated macrophages (Chensue, Remick et al.
1988; Takeichi, Saito et al. 1994), but many different cell types can produce it
under appropriate stimulation. These cell types include lymphocytes, fibroblasts,
neutrophils, smooth muscle cells, mast cells, adipocytes and adult cardiomyocytes
(Steffen, Ottmann et al. 1988; Hart, Vitti et al. 1989; Sidhu and Bollon 1993;
Larrick and Kunkel 1988; Kapadia, Lee et al. 1995). TNFs secretion appears
after 2 hours of cultured macrophage stimulation, peaks at 4-8 hours and
disappears within 12 hours. This cytokine is synthesized on demand, and it is not
stored in the cytoplasm. Production of TNF-α is tightly regulated, both at the
transcriptional and at the post-transcriptional level. LPS, viral, fungal, and
parasital agents, enterotoxin, immune complexes, IL-1, IL-2 can induce the
synthesis of TNF-α. Glucocorticoids and prostaglandin E2 inhibit TNF-α
synthesis at the transcriptional and post-transcriptional level (Beutler, Han et al.
1992). Physiological antagonists such as transforming growth
factor−β (TGF−β), IL-4 and IL-10 regulate TNF-α synthesis (Flynn and Palladino
1992; Hart, Vitti et al. 1989; Fiorentino, Zlotnik et al. 1991).
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Two TNF-receptors have been described, present on almost all nucleated cell
types: TNFR1 (or TNFRI) and TNFR2 (or TNFRII), with a molecular mass of 55
kD and 75 kD, respectively (Vandenabeele, Declercq et al. 1995). Both the
receptors belong to the TNFR superfamily, also including Fas, CD40, CD27, and
RANK (Idriss and Naismith 2000). The receptors have a cytoplasmic domain and
a transmembrane helix, which recognizes TNF-α  t h r o u g h   a N-terminal
extracellular ligand-binding domain (Idriss and Naismith 2000). Recently, two
soluble circulating TNFRs, 55 and 75 kD respectively, have been described
(Ferrari, Bianchetti et al. 1995). These are membrane-bound TNFR that have
been proteolytically cleaved from the cell membrane, and they can bind and
inactivate TNF-α (Ferrari, Bianchetti et al. 1995).
TNF-α has different biological activities mediating various physiologic and
pathologic processes, such as inflammation, cancer, cachexia, septic shock, cell
proliferation and differentiation (Fiers, Beyaert et al. 1996; Wallach, Boldin et al.
1997; Vilcek and Lee 1991). It has also been implicated in the pathogenesis of
different human cardiac diseases, such as myocarditis, dilated cardiomyopathy,
heart failure, myocardial infarction, cardiopulmonary bypass, allograft rejection,
ventricular remodeling, apoptosis and heart failure (Levine, Kalman et al. 1990;
Krown, Page et al. 1996; Satoh, Nakamura et al. 1997; Kurrelmeyer, Michael et
al. 2000; Sivasubramanian, Coker et al. 2001).
TNF-α transgenic and deficient mice from different strains were generated in the
last years. Transgenic mice generated from C57BL/6J mice overexpressing TNF-
α specifically in the heart have been shown to develop left ventricular dilatation
and remodeling during the first three months of age (Sivasubramanian, Coker et
al. 2001). Other transgenic mice generated from FVB mice showed dilated
cardiomyopathy leading to congestive heart failure (Kubota, McTiernan et al.
1997). C57BL/6J mice lacking TNF-α gene have been reported to reduce infarct
size, chemokine and adhesion molecules expression and leukocyte infiltration
(Maekawa, Wada et al. 2002). In marked contrast, recent studies indicate that
TNF-α  production can also have a beneficial role protecting the myocardium
against viral myocarditis and ischemic injury (Wada, Saito et al. 2001;
Kurrelmeyer, Michael et al. 2000; Sack, Smith et al. 2000). Wada et al. (Wada,
Saito et al. 2001) using C57BL/6J mice generated TNF-α deficient mice. They
showed that after induction of acute myocarditis by infection with
encephalomyocarditis virus the lack of this cytokine resulted in failure of
elimination of infectious agents. In addition, the use of deficient mice lacking
both TNFR1 and TNFR2 receptors showed that endogenous TNF-α  protects
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cardiac myocytes against apoptosis after acute ischemic injury (Kurrelmeyer,
Michael et al. 2000).
1.6. TNF-α and MAPKs
The SAPK/JNKs pathway can be activated by TNF-α  (Liu, Hsu et al. 1996; Ip
and Davis 1998; Kyriakis and Avruch 1996; Modur, Zimmermann et al. 1996)
(Fig. 3).
TNF-α binds to two receptors: TNFR1 and TNFR2. The stimulation of these
receptors activates different signaling transduction pathways that result either
in apoptosis or cell survival.
Ligand-induced trimerization of the TNFR1 results in the recruitment of the
cytosolic TNFR-associated death domain (TRADD) proteins (Fig. 3). After its
binding with TNFR, TRADD induces the binding of two additional and necessary
proteins that act as signal transducers: TNFR-receptor-associated factor-2
(TRAF2) and receptor interacting protein (RIP), which contain a death domain
that participates in both activation of NF-kB (through SAPK/JNKs activation)
and promotion of apoptosis (through p38 activation) (Hsu, Xiong et al. 1995; Hsu,
Shu et al. 1996; Natoli, Costanzo et al. 1997) (Fig. 3). This signaling cascade
induces activation of SAPK/JNKs, NF-kB, p38-MAPK, and AP-1 complex through
MEKK phosphorylation, which in turn regulate genes involved in inflammatory
response, cell survival, and adaptation (Roulston, Reinhard et al. 1998; Wulczyn,
Krappman et al. 1996; Liu, Hsu et al. 1996; Natoli, Costanzo et al. 1997).
Activation of TNFR1 by way of TRADD has been also shown to stimulate
apoptosis by activating the caspase 8 cascade through a member of
FADD/MORT-proteins (which also participates in the transduction of Fas-
induced apoptotic signals), which selectively induce apoptosis through
SAPK/JNKs activation (Hsu, Xiong et al. 1995; Hsu, Shu et al. 1996; Liu, Hsu et
al. 1996; Darnay and Aggarwal 1997; Natoli, Costanzo et al. 1997) (Fig. 3)
TNFR2 has been only associated with the induction of survival activating
SAPK/JNKs, NF-kB, through TRAF2, that is directly bound to TNFR2 (Liu, Hsu
et al. 1996; Darnay and Aggarwal 1997).
1.7. Innate immunity
The immune system is composed by two components: the innate and the
adaptative immune system (Medzhitov and Janeway 1998). The innate immune
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system is a preprogrammed nonspecific host defense mechanism against
pathogens. It is based on non-clonal (or germ-line encoded) receptors that
recognized non-self molecular patterns. It is characterized by activation of
myeloid-derived cells (such as natural killer cells, neutrophils, and monocytes/
macrophages), which secrete pro-inflammatory cytokines and chemokines
controlling recruitment and activation of leukocytes at the sites of infection
(Medzhitov and Janeway 1998). The adaptative immune system uses somatically
generated antigen receptors, which are cloned and distributed on T cells and B
cells (Medzhitov and Janeway 1998). It has been proposed that the innate
immune system not only has a role in the early phase of defense but also in the
activation of the subsequent, clonal response of adaptative immunity controlling
the expression of costimulatory molecules (cytokines and chemokines)
(Hoffmann, Kafatos et al. 1999).
The signal transduction for the activation of the innate immune cytokine cascade
stars with extracellular pattern-recognition molecules (e.g. LPS) that activate
membrane receptors called Toll-like receptors (Hoffmann, Kafatos et al. 1999).
The Toll-like receptors interacting with adapter molecules and kinases through
their “death domains” direct intracellular signaling events that lead to TRAF6
activation, MAPKK kinases phosphorylation with final NF-kB translocation into
the nucleus. The activation of NF-kB lead to the expression of kB binding site
genes encoding IL-1β, IL-6, IL-8 necessary for initiating the adaptative immune
response (Hoffmann, Kafatos et al. 1999).
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1.8. Innate immunity and ischemic preconditioning
Very recently, the innate immune system has been proposed as an integral part
of ischemic preconditioning (Smith, Lecour et al. 2002). Smith et al. (Smith,
Lecour et al. 2002) have postulated that ischemic preconditioning could activate
an innate (intrinsic) cytoprotection program leading to promote cardiomyocyte
survival through Toll-like receptor activation by ischemia and/or reperfusion.
Intracellular generation of reactive oxygen species by ischemia and/or
reperfusion could facilitate NF-kB translocation to the nucleus with subsequent
transactivation of cytokines (Smith, Suleman et al. 2002). TNF-α, a component of
the innate immune system plays a crucial role in ischemia/reperfusion injury.
The role of TNF-α  in ischemia/reperfusion has been associated with the
induction of NF-kB activation, thereby inducing chemokines and adhesion
molecules production and promoting leukocyte infiltration (Frangogiannis,
Lindsey et al. 1998; Maekawa, Wada et al. 2002). Smith et al. proposed that the
recruitment and activation of inflammatory cells and the production of cytokines
play a role not only in the healing and remodeling process after myocardial
infarction but also in the cardioprotective effect promoted and initiated by
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ischemic preconditioning. This group and others have proposed an association
between TNF-α  production and ischemic preconditioning in different animal
models (Smith, Lecour et al. 2002; Smith, Suleman et al. 2002). The possible
cardioprotective pathway activated by TNF-α during ischemia or
ischemia/reperfusion is poorly understood but it has been proposed to be
mediated by MAPKs activation (Baines, Cohen et al. 1999; Bogoyevitch,
Gillespie-Brown et al. 1996; Martire, Fernandez et al. 2001).
1.9. Ubiquitin
Ubiquitin is a highly conserved small globular protein of 76 amino acids and it
belongs to the heat-shock proteins (Mayer, Arnold et al. 1991; Lowe and Mayer
1990). It is present in all eukaryotic cells and occupies a pivotal role in the
regulation of protein turnover and degradation in both, normal metabolic
processes and in diseases where degenerative processes occur (for review see
Weissman 2001). Its covalent conjugation to other proteins is essential for
proteasomal degradation but ubiquitin itself does not degrade proteins. It serves
only as a tag marking proteins for degradation. Ubiquitin conjugation
(ubiquitylation or ubiquitination) to proteins occurs in a multistep process,
involving at least three types of enzymes (Weissman 2001). First, an ubiquitin-
activating enzyme called E1 binds and actives ubiquitin in an ATP-dependent
process forming a thiol-ester bond with the carboxy-terminal glycine of ubiquitin.
Second, an ubiquitin-conjugating enzyme, E2, accepts ubiquitin from E1 by a
trans-thiolation reaction, involving the carboxyl terminus of ubiquitin. Finally, a
ubiquitin protein ligase, E3, catalyses the transfer of ubiquitin from the E2
enzyme to the ε-amino group of a lysine residue of the substrate leading to its
ubiquitylation (Weissman 2001). Only a chain of four or more ubiquitin
(multiubiquitylation) targets a protein for proteasomal degradation being
adequate as a proteasome-targeting signal, whereas a single ubiquitin
(monoubiquitylation) tag does not. Ubiquitylated proteins are recognized by 26S
proteasomes. The 26S proteasomes are responsible for ATP-dependent
degradation of the target proteins and release of ubiquitin. They are formed by
two different components, one is the proteolytic unit (20S), that catalyses the
protein degradations, and the other is a multisubunit regulatory complex (19S),
that has a role in unfolding the proteins, guiding them into the degradative
tunnel formed by 20S subunits (Weissman 2001). The result is a collection of
small peptides from which ubiquitin is released and recycled (Field and Clark
1997).
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Ubiquitin is involved in many cell processes, such as cell-cycle progression, signal
transduction, receptor-mediated endocytosis, transcription, cell proliferation and
differentiation, quality control in the endoplasmic reticulum, organelle
biogenesis, spermatogenesis, protein transport, antigen processing and
embryonic development (Weissman 2001; Mayer, Lowe et al. 1989; Thompson
1995; Hu, Martone et al. 2000; Field and Clark 1997). In addition, ubiquitin is an
important protein induced by cell stress (Weissman 2001; Mayer, Arnold et al.
1991; Thompson 1995; Hu, Martone et al. 2000; Field and Clark 1997). In fact, it
has been shown that an upregulation of the ubiquitin gene occurs in
inflammation, DNA repair, apoptosis, ischemic neuronal death, and heart failure
(Weissman 2001; Mayer, Arnold et al. 1991; Thompson 1995; Field and Clark
1997).
1.10. Complement 9
 Complement (a member of the immune system) is a cytotoxic host defense
system that was identified initially because of its cytolytic effects. It is composed
by ≈20 intravascular plasma proteins, which are subdivided into two cascade
systems, the classic and alternative complement pathways. The classic pathway
is achieved with the involvement of immunoglobulins in the activation of the
complement, while the alternative does not (Muller-Eberhard 1988). The
activation of the complement system by the classical or the alternative pathway
produces complement fragments that have important roles in the inflammatory
response. Activation of the complement system produces direct tissue injury
through the formation of the membrane attack complement (MAC) by
complement 5b-9, followed by its insertion into host cell membranes (Morgan
1989). Rapid cell death can occur through disruption of cellular integrity (Morgan
1989).
Complement has a role in some physiological processes, such as the induction of
the humoral immune response, in the elimination of immune complexes and in
the protection against bacterial and viral infections. Complement activation and
deposition occurs in dermatomyositis (Kissel, Halterman et al. 1991), myasthenia
gravis (Tsujihata, Yoshimura et al. 1989), X-linked vacuolated myopathy
(Villanova, Louboutin et al. 1995), and inflammation (Mulligan, Schmid et al.
1996). Activation of the complement system has been also implicated in the
pathogenesis of myocardial ischemia/reperfusion injury (Weiser, Williams et al.
1996; Vakeva, Morgan et al. 1994; Weisman, Bartow et al. 1990; Hill, Lindsay et
al. 1992). Components of the complement system such as complement 3,
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complement 4, complement 5, complement 9 and the MAC have been identified in
experimentally infarcted tissue as well as in human ischemic myocardium
(Mathey, Schofer et al. 1994). Complement 5b-9 accumulates rapidly in ischemic
myocardium during reperfusion (Mathey, Schofer et al. 1994). The reperfusion
plays a critical role in mediating complement deposition because in its absence
the complement accumulation occurs only as a late event (Mathey, Schofer et al.
1994). In a rabbit model of ischemia/reperfusion it has been shown that local
production of complement proteins may contribute significantly to the degree of
ischemic injury to the myocardium and that complement expression is
augmented by reperfusion (Yasojima, Kilgore et al. 1998).
Recently, the use of complement 9 immunostaining has been proposed for the
identification of cardiomyocyte necrosis after myocardial ischemia (Robert-
Offermann, Leers et al. 2000; Lazda, Batchelor et al. 2000).
1.11. Major histocompatibility complex II
Major histocompatibility complexes (MHCs) were discovered as proteins causing
rejection when skin (graft) from a mouse (donor) strain was implanted (grafted)
to a back of another strain mouse (recipient) and the graft soon died (Klein 1990;
Darnell, Lodish et al. 1990). The graft implanted is destroyed by the recipient’s
immune system because the donor’s cells express a fair number of proteins on
their surfaces that are different from those expressed by the recipient and cause
the rejection (Klein 1990; Darnell, Lodish et al. 1990). Those molecules act as
antigens, in the same way as molecules from invading virus or bacterium. They
act as histocompatibility antigens, encoded in a set of clustered loci of
histocompatibility genes. The basis for the ability of MHCs to elicit graft rejection
is that each animal of a given species has MHCs genes that differ in sequence
from the MHCs genes of other individuals. For this reason the MHCs are said to
be polymorphic.
The MHCs are divided into two classes, I and II (Klein 1990; Darnell, Lodish et
al. 1990). The MHC class I are glycoproteins that can be divided in three
functional domains: external, transmembrane, and cytoplasmic (Klein 1990). The
external region consists of two-chain proteins with one highly polymorphic
component composed by three domains α 1, α 2, α 3, and one constant chain called
β2-microglobulin (β2-m) (Klein 1990). The transmembrane region is composed by
mostly hydrophobic amino acids arranged in an α-helix. The cytoplasmic region
composed by the COOH terminal has the potential of interacting with elements
of the cytoskeleton (Klein 1990; Darnell, Lodish et al. 1990).
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The MHC class II are heterodimers consisting of one α  and one β  chain. Both the
α and β chains consist of an external region, a connecting peptide, a
transmembrane region, and a cytoplasmic tail (Klein 1990). The external region
is composed of two domains, α1and α2 or β1and β2. The connecting peptide
connects the external domains with the transmembrane region arranged in both
α and β chains. The cytoplasmic tail is arranged also in both, α and  β chains
(Klein 1990). 
The MHC I is expressed on all somatic cells in adults at high concentration in
some cells such as lymphocytes, and at low concentration in other cells such as
fibroblasts or neurons. MHC II is constitutively high expressed only in certain
cells such as macrophages, B lymphocytes and activated T lymphocytes (in
human but not in mice), and virally infected human T lymphocytes. Its
expression can be also induced by stimulation (for example with interferon-γ) in
many different cell types such as macrophages, dendritic cells, melanoma cells,
some epithelial cells, and same parenchymal cells such as thryroid and
pancreatic cells (Klein 1990).
The function of MHCs is to expose foreign antigens to T lymphocytes on the
surface of an antigen-presenting cell (Klein 1990). The T-cell receptor (TCR)
recognizes foreign antigens (usually peptides) together with the MHC molecule:
nonself is recognized in the context of self. Class I MHC binds peptides from
intracellular proteins, while class II MHC binds peptides from extracellular
proteins.
1.12. Objective of the present study
For the realization of the present Thesis we used a transgenic (TG) strain of mice
that overexpress murine MCP-1 in the heart (Kolattukudy, Quach et al. 1998).
Already published data regarding the MCP-1 TG phenotype showed that young
(0-2 months old) TG mice exhibit focal accumulation of monocytes/macrophages
in the myocardial interstitium leading to ischemic cardiomyopathy and a gradual
loss of myocytes in elderly animals (Kolattukudy, Quach et al. 1998; Moldovan,
Goldschmidt-Clermont et al. 2001). Therefore, we have postulated the hypothesis
that activated leukocytes expressing TNF-α in the heart of MCP-1 TG mice might
confer myocardial protection against ischemia by activating the MAPKs pathway.
To test this hypothesis we investigated the cardiac resistance to ischemia in TG
(~ 4 months old) and control (WT) (non-transgenic mice from the same litter)
mice with and without injection of the SAPK/JNKs inhibitor D-JNKI1.
Histopathological examinations of MCP-1 TG hearts were performed, as well as
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quantitative analysis of TNF-α, phosphorylated-SAPK/JNK1/2, phosphorylated-
ERK1/2, and phosphorylated-p38 protein levels. Finally, in order to establish a
pattern of temporal effects of MCP-1 overexpression, electron microscopy
analyses of hearts from 1 day, 1 months, 2 months, and 6 months old TG mice
were performed and TG mice from 6 months old were used for quantitative
histological analysis for ubiquitin, complement 9, and MHC II antibodies.
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2. Material and Methods
2.1. Generation of MCP-1 TG mice
The MCP-1 TG mice have been generated in the Ohio State University,
Columbus, Ohio (Kolattukudy, Quach et al. 1998). The construct consists of the
cDNA of the murine MCP-1 (JE) gene, that is linked downstream to the
α−cardiac myosin heavy chain promoter in order to confer cardiac specific
expression. Briefly, a Myhca clone containing the 5.5-kb promoter region of the α-
cardiac myosin heavy chain (MHC) was double digested by Sa/l and Kpnl. Then,
1.9-kb DNA element of the mouse JE-MCP-1was generated by PCR amplification
and cloned into pUC 19 plasmid. The MCP-1-pUC 19 plasmid was amplified by
PCR tecniques using a nucleotide primer containing Sa/l and Kpnl restriction
sites. The PCR products cleaved with Sa/l and Kpnl were ligated to the Sa/l-
Kpnl-digested Myhca clone to obtain the construct pMHC-MCP-1. The generated
plasmid pMHC-MCP-1 was then digested with Notl/Kpnl to obtain a DNA
fragment of 7.4-kb. This DNA fragment was microinjected into one-cell FVB/N
embryos. The surviving embryos were implanted into pseudopregnant C3B6F1
foster mothers. The TG and WT mice were selected by PCR and Northern blot
analysis.
2.2. Animals
The total number of mice used for all the experiments was 43 WT, 3-10 months
old and 57 TG 0-9 months old.
Housing and handling of the animals was in accordance with the American
Physiological Society guidelines for animal welfare and the Bioethical Committee
of the District of Darmstadt, Germany.
2.3. Fourty-five-min coronary artery occlusion (CAO)
2.3.1. Experimental protocol
We performed 45-min of experimental coronary artery occlusion (CAO) in WT
(n=5) and TG (n=5) mice. The mice were anaesthetized with an intraperitoneal
injection of 10%Ketamine (0.1 mg/g body weight) and 2%Xylazin (0.005 mg/g
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body weight) in 9% NaCl solution. For each mouse we used approximately
0.16 ml of Ketamin solution, 0.16 ml of Xylazin solution and 0.32 ml of NaCl
solution. When necessary half dose of anaesthetic was re-injected
intraperitoneally. After the induction of anaesthesia, the chest coat was shaved
and the trachea was intubated with a 1.1 mm steel tube connected to an animal
ventilator. Heparin solution (125 IU, 0.025 ml) was injected intraperitoneally to
prevent microthrombus formation during occlusion and reperfusion. The body
temperature was kept at 37°C. Heart function was continuously recorded with a
3-lead surface electrocardiogram (ECG) inserted under the skin of thorax,
abdomen, and flank. After opening the skin overlying the left part of the thoracic
cage the pectoral muscles were prepared free and retracted with 6-0 silk suture.
Subsequently, the chest was opened through the third or fourth intercostal space
by dissecting the intercostal muscles. Lungs were retracted with a moistened
sponge, and a retractor was introduced to gain access to the thoracic cage.
Ligation was performed proximal to the main branch of the left coronary artery,
using a 6-0 prolene suture and a PE-10 tube was also used to allow removal of
the ligation. When perfusion was stopped by ligation, changes in the ECG and
tissue color were assessed. After 45 min, the tube was removed and the
reperfusion of the coronary artery visually assessed and confirmed by the
changes in the ECG. A 0.075 ml propidium iodide solution (Sigma, 0.05% w/v in
0.9% NaCl solution) was perfused via a catheter into the right carotid artery and
allowed to circulate for 10 min. After the short reperfusion time, the coronary
artery was re-occluded and a solution (0.075 ml approximately) of thioflavin S
(Sigma, 4% w/v in 0.9% NaCl solution) was injected into the carotid artery for a
few seconds. The heart was then removed, the right ventricle excised, and the left
ventricle cryopreserved with nitrogen-cooled methylbutane.
2.3.2. Experimental protocol for the SAPK/JNKs inhibitor D-JNKI1
D-JNKI1, a novel SAPK/JNKs inhibitor, was injected in TG and WT mice. A
specific cytoplasmic inhibitor of SAPK/JNKs, called JNK interacting protein-
1/IB1 (JIP-1/IB1), was characterized and cloned. JIP-1 binding specifically to
JNKs causes cytoplasmic retention of JNKs and specific inhibits JNK signal
transduction pathway activation (Dickens, Rogers et al. 1997). D-JNKI1 was
generated from JIP-1/B1 inhibitor. A 500 µl solution of the SAPK/JNKs inhibitor
D-JNKI1 (Alexis Biochemicals, 0.25 mg/body weight in 0.9% NaCl
solution/DMSO) was injected into the tail artery in TG (n=5) and WT (n=4) mice
30-min before CAO. Alternatively,  500 µl solution of DMSO (0.5% in O.9% NaCl
solution) were also injected into the tail artery of TG (n=2) and WT (n=2) mice 30-
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min before CAO. After the inhibitor injections, we performed 45 min CAO as
described in 2.3.1.
2.3.3. Determination of infarct size
Propidium iodide was employed to determine the infarct size for 45-min of CAO.
Propidium iodide is routinely used as nuclear marker in cell culture (Laake,
Haug et al. 1999; Kang, Haunstetter et al. 2000) and flow cytometry (O´Brain
and Bolton 1995) studies to label necrotic cells. During myocardial infarction, the
loss of membrane integrity allows the propidium iodide to enter the necrotic cells
and stain the nucleus by its specific binding to DNA. This staining results in a
red fluorescent signal that delineates infarcted areas. Propidium iodide staining
has been successfully employed by other authors to measure infarct size in
experimental coronary artery ligation (Ito, Schaarschmidt et al. 1997; Wolff,
Chien et al. 2000). These authors demonstrated that in esperiments with a short
period of reperfusion, propidium iodide is a more appropriate method to quantify
the infarcted area when compared to the more commonly used triphenyl
tetrazolium chloride (TTC). TTC reacts with dehydrogenases in the presence of
the co-enzyme NADH producing a red colored precipitate (Klein, Pushmann et al.
1981). Necrotic cells lose their ability to retain NADH and show a pale color when
incubated with TTC, while viable cells, which contain NADH, react with TTC and
are stained in red. The TTC method requires long reperfusion time to wash out
dehydrogenases and NADH from the necrotic tissue, and avoid understimation of
the infarcted area (Ito, Schaarschmidt et al. 1997; Wolff, Chien et al. 2000; Klein,
Pushmann et al. 1981). As propidium iodide requires only a few minutes of
reperfusion to appropriately stain necrotic cells, this was the method of choice for
45-min CAO, where the effect of reperfusion on ischemic injury was not desired.
The endothelial cell marker thioflavin S was employed to quantify the non-risk
area of the left ventricle.
The risk area was measured and defined as the non-perfused area of the left
ventricle (thioflavin S-negative).
Left ventricular cryosections 14 µm thick were cut and photographed under
fluorescent light with a DM-RB Leica microscope. The total left ventricle, risk
area and infarct area were determined using computer assisted planimetry
software NIH Image. Finally, three ratios were obtained: infarct area/risk area
(IA/RA), infarct area/left ventricle (IA/LV), and risk area/left ventricle (RA/LV).
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2.4. Fourty-five-min CAO followed by 3 days of reperfusion
2.4.1. Experimental protocol
We performed 45-min CAO followed by 3 days of reperfusion (45-min CAO+3-day
R) in WT (n=4) and TG (n=4) animals. The animal preparation for CAO was the
same as for 45-min CAO. Ligation was performed proximal to the main branch of
the left coronary artery, using a 6-0 prolene suture and a PE-10 tube was also
used to allow removal of the ligation. After 45 min, the tube was removed and the
reperfusion of the coronary artery visually assessed and confirmed by the
changes in the ECG. The chest was closed in layers using a 4-0 silk suture. The
animal ventilator was disconnected when the mice started to wake up, and the
mice were kept warm with a heat lamp until complete recovery.
2.4.2. Determination of infarct size
TTC was employed to determine the infarct size after 45-min CAO+3-day R.
Three days after 45 min CAO the animals were killed by anesthetic overdose
(10%Ketamin, 2%Xylazin) injected intraperitoneally, the heart was excised, the
right ventricle removed, and the left ventricle was frozen for 5-10 min to allow to
easily cut it in transverse slices. The slices were weighed and incubated at 37°C
in 1% TTC (Sigma) in phosphate saline buffer (PBS) solution, pH 7.0, for 20 min.
PBS solution (pH 7.0 and pH 7.4):
NaCl 7.948 g
KCl 0.2 g
KH2PO4 0.2 g
NaHPO4H20 1.775 g
Distilled water 1 L
Adjust the pH with HCl or NaOH.
After incubation with TTC, the upper and the bottom part of each slide were
photographed and the pictures used for planimetric analysis. The left ventricle
and the infarct area (recognized by the pale color due to lack of TTC staining)
were determined using computer assisted planimetry with NIH Image software.
These measurements provided the IA/LV ratio.
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2.5. Three-day CAO
2.5.1. Experimental protocol
The animal preparation for 3-day CAO was the same as for 45-min CAO.
Permanent ligation was performed using a 6-0 prolene suture. After assessment
for coronary ligation efficiency (changes in the ECG and tissue color), the chest
was closed in layers using a 4-0 silk suture. The animal ventilator was
disconnected when the mice started to wake up, and the mice were kept warm
with a heat lamp until complete recovery.
2.5.2. Determination of infarct size
TTC was employed to determine the infarct size after 3-day CAO.as described in
2.4.2..
2.6. Western blot analysis
The hearts of WT (n=12) and TG (n=12) animals were excised, snap-frozen in
liquid nitrogen and stored at –80 °C until use. The tissue was homogenized with
ice-cold buffer containing 20 mM tris-HCl, 250 mM sucrose, 1.0 mM EDTA, 1.0
mM EGTA, 1.0 mM DTT, 0.1 mM sodium orthovanadate, 10 mM NaF, and 0.5
mM PMSF.
Ice-cold buffer preparation (100 ml):
Tris 0.2422 g
Saccarose 8.5575 g
EDTA 0.037224 g
EGTA 0.3804 g
DTT 0.015425 g
Sodium orthovanate 0.001839 g
NaF 0.04195 g
PMSF 0.00871 g dissolved in 500 µl ethanol
Add distilled water until 100 ml and adjust the pH 7.4. The ice-cold buffer has to
be frozen for 15 min at –80°C until use.
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The homogenate was centrifuged at 4°C and 13,000 g for 30 min and the
supernatant (cytosolic fraction) was kept for protein analysis. The Bio-Rad
Protein Assay (Bio-Rad Laboratories) was used to assess the equivalent amount
of proteins for immunoblot analysis following the manufacture’s instructions. We
used Laemmli Sample Buffer (Bio-Rad Laboratories) (2:1, Laemmli Sample
Buffer, cytosolic fraction, respectively) and 5 min denaturation by heating at
95°C for electrophoresis protein preparation.
Laemmli Sample Buffer solution:
Laemmli Sample Buffer 950 µl
Mercaptoethanol 76 µl
Electrophoresis was performed at 120 Volt in 10% and 18% Tris-HCl ready gel
(Bio Rad, 10 wells each one for 30 µl of probe solution) in running buffer for 1-3
hours depending on the size of the protein used. Fifteen µl of weight reference
marker (MultiMark, Multi-Colored Standard; Invitrogen) was added in every
electroforesis.
Running buffer (1 l):
SDS 1 g
TRIS 3.03 g
Glycin 14.41 g
Distilled water 1 l
The proteins were transferred onto nitrocellulose membranes using the
electrophoresis machine at 200 mA for 2 hours in transfer buffer.
Transfer buffer (1 l):
TRIS 3.03 g
Glycin 14.41 g
Methanol (20%) 200 ml
Distilled water 800 ml
The membranes were then blocked with 5% nonfat dry milk in tri-phosphate
saline buffer (TBS) overnight at 4°C (alternatively, 3 hours at room temperature).
TBS:
TRIS 2.42 g
NaCl 8.0 g
Distilled water 1 l
Adjust the pH 7.4.
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After blockage, the membranes were incubated with the first antibody in TBS
overnight at 4°C (alternatively, 3 hours at room temperature). Polyclonal
antibodies against JNK1 (Santa Cruz Biotechnology, 1:500 dilution),
phosphorylated-SAPK/JNK1/2 (Cell Signaling Technology, 1:500 dilution), ERK 2
(Santa Cruz Biotechnology, 1:500 dilution), phosphorylated-ERK1/2 (New
England Biolabs, 1:500 dilution), p38 (Santa Cruz Biotechnology, 1:500 dilution),
phosphorylated-p38 (Cell Signaling Technology, 1:500 dilution), and TNF-α
(Santa Cruz Biotechnology, 1:200 dilution) were used. After washing (6 x10 min)
with TBS, the membranes were incubated 2 hours with peroxidase-conjugated
anti-rabbit IgG in TBS (Amersham, 1:1000 dilution). The ECL-system
(Amersham Pharmacia Biotech) was used for signal detection following the
manufacture’s instructions and quantification was performed on STORM 860
(Amersham Pharmacia Biotech), using ImageQuan software.
2.7. Terminal dUTP deoxynucleotidyl transferase nick end-
labeling (TUNEL) assay
TUNEL staining was performed in three random cryosections from each heart of
WT (n=3) and TG (n=5) mice. The In Situ Cell Death detection Kit, Fluorescein
(Roche Diagnostic) was used according to the manufacture’s instructions.
Cryosections of duodenum were used as positive control.
2.8. Electron microscopy
The hearts from additional WT (n=2) and TG (n=9) animals were perfusion-fixed
with a mixture of 2% paraformaldehyde and 1% glutaraldehyde in PBS solution
(pH 7.4) and immersed in 3% glutaraldehyde.
3% glutaraldehyde:
25% glutaraldehyde 12 ml
Cacodylate buffer without saccharose (0.1 M) 88 ml
Cacodylate buffer (0.1 M):
Na-cacodylate 21.4 g
Saccharose 75 g
Distilled water 1l
Adjust the pH 7.4.
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The hearts were then post-fixed with osmium tetroxide, dehydrated in a series of
ethanol, and embedded in epoxy resin with the following protocol using a Lynx
microscopy tissue processor Reichert Jung:
Osmium + Veronal-acetate with 4% saccharose solution 2 hours 4°C
Veronal-acetate with 7.5% saccharose solution 3 x 15 min 4°C
30 % ethanol 15 min 4°C
50% ethanol 15 min 4°C
70% ethanol with 0.5% Uranyl 15 min 4°C
90% ethanol 15 min 4°C
100% ethanol 2 x 15 min 4°C
Propylenoxide 2 x 15 min 4°C
Propylenoxide-Epon 1:1 15 min 4°C
Epon 3 x 60 min 37°C
Osmium(tetroxide) solution:
Stock solution:
OsO4 1 g
Distilled water 16.4 g
Keep in the refrigerator until used.
Used solution:
Veronal acetate (from stock solution) 2 ml
OsO4 (from stock solution) 1 ml
Adjust the pH 7.4.
Veronal acetate buffer:
Stock solution:
Na-Acetate (CH3COONa3H2O) 9.7 g
Veronal-Na (Na-5.5-Diethyl-barbituracid) 14.7 g
Distilled water 250 ml
Dissolve at room temperature and than add distilled water until 500 ml.
Used solution:
Veronal-Acetate (from stock solution) 20 ml
HCl (0.1 N) 20 ml
Ditilled water 60 ml
Add 4% or 7.5% of saccharose and adjust the pH 7.4.
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Ultramicrotome sections were counterstained with uranyl acetate and Reynolds
lead citrate with the following protocol:
• 2 min in Uranyl-Acetate solution
• 1 min wash in distilled water
• 2 min in Reynold lead citrate solution
• 1 min wash in distilled water
Uranyl acetate:
3% uranyl acetate in distilled water.
Reynolds lead citrate solution:
Stock solution:
Pb(NO3)2 1.33 g
Na-Citrate 1.76 g
NaOH (1 N) 8 ml
Dissolve Pb(NO3)2 and Na-Citrate with 30 ml distilled water shaking for 1 hour,
then add NaOH (1 N) and distilled water until 50 ml. The pH has to be 12, if not,
the protocol has to be repeated because it is not possible adjust it.
Used solution:
Stock solution 10 ml
Distilled water 10 ml
Add NaOH (1 N) to obtain pH>11. Filter the solution with a Millipore-filter and
keep it in the dark and in a closed bottle.
The photographs and evaluations were performed using a Philips CM10 electron
microscope.
2.9. Histology and immunohistochemistry
For the analysis of specific structural changes due to MCP-1 overexpression,
additional animals (WT, n=7; TG, n=10) were killed by anesthetic overdose
(10%Ketamin, 2%Xylazin) injected intraperitoneally. The hearts were dissected
and cryopreserved with nitrogen-cooled methylbutane and stored at -80°C until
used. Alternatively, the hearts were perfusion fixed, first with 0.01% adenosine
in PBS solution (pH 7.4), and then with 4% paraformaldehyde in PBS solution
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(pH 7.4). After perfusion/fixation, the hearts were fixed in 4% paraformaldehyde
for 48-72 hours. After the fixation, the hearts were embedded in paraffin with the
following protocol:
• wash in distilled water, 1 hour and 30 min
• dehydration with:
30% ethanol, 1 hour and 30 min
50% ethanol, 1 hour and 30 min
70% ethanol, 1 hour and 30 min (or overnight)
80% ethanol, 1 hour and 30 min
95% ethanol, 1 hour and 30 min
100% ethanol, 1 hour and 30 min (x2)
Xylol, 1 hour and 30 min (x2)
• bath with xylol+paraffin (1:1), 1 hour and 30 min at 60°C
• bath in paraffin, overnight at 60°C
• re-bath in paraffin, 1 hour and 30 min at 60°C
• preparation of the block at room temperature.
The paraffin blocks or cryopreserved hearts were cut in 5 µm sections and
stained with hematoxilin and eosin (H&E).
H&E staining:
• desparaffination in xylol (only for paraffin blocks), 5 min (x3)
• hydration (only for paraffin blocks) with:
95% ethanol, 5 min
70% ethanol, 5 min
50% ethanol, 5 min
• staining with Delafield-hematoxilin, 10-15 min
• staining with Yellow-eosin, 7-10 min
•dehydration with:
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95% ethanol, 5-10 seconds
100% ethanol, 5-10 seconds
• Xylol, 10 min
• cover with coverglass using DPX.
For immunohistochemistry, only cryopreserved hearts were used. The following
primary antibodies were used, a FITC-conjugated monoclonal antibody against
the transferrin receptor CD 71 (Ancell, 1:100 dilution), a polyclonal antibody
against TNF-α (Santa Cruz Biotechnology, 1:20 dilution), a polyclonal antibody
against ubiquitin (Dako, 1:50 dilution), a rat monoclonal antibody against MHC-
II (MHC-II) (BMA, 1:50 dilution), a polyclonal antobody against phosphorylated-
SAPK/JNK1/2 (Cell Signaling Technology, 1:100 dilution), and a mouse
monoclonal antibody against complement 9 (NOVOCASTRA, 1:50 dilution).
Cryosections, 5 µm thick, were air dried and fixed with 4% paraformaldehyde or
ice-cold acetone for 10 min. In addition, the sections used for TNF-α and
phosphorylated-SAPK/JNKs antibodies were incubated with 3% hydrogen
peroxide for 10 min to quench the endogenous peroxidase activity. After the
washing steps (3x5 min) in PBS solution (pH 7.4), the slides were immersed in a
blocking solution containing 0.1% bovine serum albumin and 0.4% glycine in PBS
for 30 min. After incubation with the primary antibodies, the sections were
washed (3x 5 min) with PBS solution. The sections were incubated with specific
second biotinylated-antibodies for 1 hour: anti-rabbit (1:100 dilution) for
ubiquitin, anti-rat (1:100 dilution) for MHC-II, and anti-mouse (1:100 dilution)
for complement 9, respectively, and then incubated with Cy2-streptavidin (1:100
dilution) for 1 hour. All the sections, excluded those used for TNF-α  and
phosphorylated-SAPK/JNKs antibodies, were incubated with the myocyte marker
phalloidin-TRITC labelled (Sigma, 1:500 dilution) for 20 min. Finally, the
sections were incubated with the nuclear markers 4‘,6-diamidino-2-phenylindole,
dilactate (DAPI) (Molecular Probes, 1:1000 dilution) or propidium iodide (Sigma,
1:1000 dilution) for 10 min. The sections used with TNF-α  and phosphorylated-
SAPK/JNKs antibodies were incubated with peroxidase-conjugated anti-rabbit
IgG (Amersham, 1:100 dilution). Peroxidase was detected by incubation with 3,3‘-
diaminobenzidine (Sigma), and the nuclei were counterstained with hematoxilin.
Omission of the first antibodies was used as negative control. Finally, the
sections were evaluated and photographed under transmitted or fluorescent light
with a DM-RB Leica microscope or a TCSNT Leica confocal microscope.
- 32 - 2. Material and Methods
2.9.1. Quantitative immunofluorescence analysis for ubiquitin,
complement 9, and MHC II antibodies
Ten randomly  chosen cryosections from the apex to the base of hearts from WT
(n=2) and TG (N=5) mice were immunolabeled for ubiquitin, complement 9, and
MHC II as described in 2.9.. Positive-myocytes for each antibody were counted in
each section as well as the total number of myocytes using computer assistant
planimetry with NIH Image software. Finally, we obtained the number of
ubiquitin, complement 9, and MHC II positive-cardiomyocytes as a percentage of
the total number of myocytes.
2.10. Quantitative immunohistochemical analysis by
densitometry
Three randomly chosen cryosections from WT (n=3) and TG (n=4) hearts were
immunolabeled for phosphorylated-SAPK/JNK1/2 as described in 2.9. All sections
were stained and photographed using the same conditions. Twenty-four
randomly selected phosphorylated-SAPK/JNK1/2-positive myocytes were
measured from each section. Quantitative intensity level analysis was performed
using computer assistant planimetry software (NIH Image).
2.11. Statistical analysis
Results are reported as mean ± SEM. Unpaired t-test or the Mann-Whitney-U-
test was used to estimate significant differences between groups. The accepted
minimum level of statistical significance was p<0.05.
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3. RESULTS
3.1. Infarct size
3.1.1. Fourty-five-min CAO
We performed 45-min CAO in TG (n= 5) and WT mice (n=5) in order to
investigate the TG cardiomyocyte resistance to ischemia. Previous studies in our
group has demonstrated that 45-min of ischemia are enough to obtain a near
maximum infarct size in the murine heart. Fig. 4A,B shows a transversal section
of the left ventricle from a WT and a TG heart. Dead myocytes are stained in red
with propidium iodide and represent the infarct area (IA). Endothelial cells from
the non-risk area of the left ventricle (LV) are stained in blue with thioflavin S
and represent the viable myocardium not irrigated by the occluded coronary
artery. The risk area (RA) not stained appears dark and represents cardio-
myocytes irrigated by the ligated coronary artery that are still alive (propidium
iodide-negative cells). After 45-min of CAO, the infarct size was 3.7-fold reduced
in TG mice as compared to WT (IA/RA: 14.7 ± 2.6% versus 52.0 ± 2.4%, IA/LV:
7.8 ± 1.5% versus 29.0 ± 1.5%) (Fig. 4C). The risk area did not differ significantly
between TG and WT animals (RA/LV: 53.5 ± 1.2% versus 50.9 ± 0.9%) (Fig. 4C).
Quantification of the ratio IA/RA, IA/LV and RA/LV in TG and WT animals is
represented in Fig. 4C.
Fig. 4. (A) and (B) Transverse section (14 µm) of the left ventricle from WT (A)
and TG (B) animals after 45-min of CAO. Dead myocytes are stained in red with
propidium iodide. Endothelial cells from the non-risk area are stained in blue
with thioflavin S. The risk area is not stained and appears dark. x50. (C)
Quantification of the ratios IA/RA, IA/LV, RA/LV, in WT (n=5) and TG (n=5)
animals after 45-min of CAO. The statistical significance in the infarct size
between WT and TG mice is reported.
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3.1.2. Three-day CAO
In order to check if the reduction in infarct size observed after 45-min of CAO in
MCP-1 TG mice is still induced after long-term ischemia, we performed long-term
(3-day) CAO in WT and TG mice. The Fig. 5A,B shows a transversal section of
the left ventricle from a WT and a TG heart after 3-day of CAO. Dead myocytes
(IA) are showed in a pale color by the reaction with TTC, while alive myocytes
are stained in red with the reaction with TTC. The infarct size did not differ
significantly between TG and WT animals (IA/LV: 33.9 ± 4.1%versus 31.8 ± 2.9%)
(Fig. 5A,B). The quantification of the ratio IA/LV is represented in Fig. 5C.
Fig. 5. (A) and (B) Left ventricle slices from WT (A) and TG (B) hearts after 3-
day of CAO. Viable myocardium is stained in red by the reaction with TTC.
Infarct area appears pale due to lack of TTC staining. (C) Quantification of the
ratio IA/LV in WT (n=3) and TG (n=4) animals after 3-day of CAO. No
significant difference in the infarct size can be detected between WT and TG
animals at this time point after coronary occlusion.
3.1.3. Fourty-five-min CAO+3-day R
In order to check if the reduction in infarct size observed after 45-min of CAO in
MCP-1 TG mice was induced permanently, we performed 45-min of CAO followed
by 3 days of reperfusion in WT and TG mice. The infarct size was significantly
decresed in TG mice when compared with WT (IA/LV: 23.2 ± 1.8% vs 30.0 ± 1.8%)
(Fig. 6).
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Fig. 6. Quantification of the ratio IA/LV in WT (n=4) and TG (n=4) after 45-
min CAO+3-day R.
3.1.4. D-JNKI1 and infarct size
In order to investigate the role of SAPK/JNKs pathway activation in the
induction of cardioprotection in MCP-1 TG mice, we injected the SAPK/JNK1/2
inhibitor D-JNKI1 before performing CAO. Injection of the inhibitor D-JNKI1
increased significantly  infarct size in TG mice as compared with untreated TG
mice (Fig. 7). In contrast, D-JNKI1-treated WT mice showed that infarct size did
not increase significantly as compared with untreated WT animals (Fig. 7).
Despide the fact that infarct size was still significantly different between
D-JNKI1-treated TG and untreated WT mice, the infarct size of D-JNKI1-treated
TG animals was not significantly different from treated WT mice (Fig. 7).
Application of NaCl/DMSO without D-JNKI1 had no influence on infarct size in
TG as well as in WT hearts (data not shown).
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Fig.7. Infarct size determination after injection of the SAPK/JNKs inhibitor
D-JNKI1 in WT (n=4) and TG (n=5) mice. WT and TG treated mice (+inh in the
figure) were compared one to each other and with WT and TG untreated mice. The
statistical significances are reported.
3.2. Western blot analysis
3.2.1. SAPK/JNK1/2
In order to check if the activation of SAPK/JNK1/2 showed different degree of
expression in the hearts of TG and WT animals we performed Western blot
analysis using an antibody against phosphorylated (activated) SAPK/JNK1/2. A
significant (1.5-fold) increase in the phosphorylated-SAPK/JNK1/2 was found in
the heart of TG animals as compared to the WT as shown in Fig. 8A,C. The
activation was induced in both, p46 and p54 respectively isoforms, of
SAPK/JNK1/2 in TG and WT mice. An antibody against JNK1 (inactivated
SAPK/JNK1/2) was used to confirm the presence of SAPK/JNK1/2 proteins in the
heart of TG and WT animals as well as equal amount of non-phosphrylated
proteins (Fig. 8B).
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Fig. 8. (A) Western blot assay of hearts from WT and TG animals using a
polyclonal antibody against phosphorylated-SAPK/JNK1/2 (p-SAPK/JNK1/2 in
the figure). The activation is induced in both, p46 and p54 respectively isoforms of
SAPK/JNK1/2. (B) Western blot assay of the same WT and TG hearts used in A,
using a polyclonal antibody against JNK1 (inactivated SAPK/JNK1/2). (C)
Quantification of phosphorilated-SAPK/JNK1/2 proteins in WT (n=4) and TG
(n=4) animals. The differences in the phosphorylated-SAPK/JNK1/2 levels
between WT and TG mice are significant for both isoforms.
3.2.2. ERK1/2
We performed Western blot analysis using an antibody against phosphorylated-
ERK1/2 in order to check if other members of the MAPKs superfamily are
activated in the MCP-1 TG animals. In hearts of TG and WT mice no differences
were found in the protein levels of phosphorylated (activated) ERK1/2 (Fig. 9A).
Western blot of ERK2 (inactivated form of ERK2) showed similar amounts of
non-phosphorylated proteins in TG and WT hearts (Fig. 9B).
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Fig. 9. (A) Western blot analysis of hearts from WT and TG mice using a
polyclonal antibody against phosphorilated-ERK1/2 (p44 and p42 isoforms,
respectively). No statistical differences in the protein levels can be detected between
WT (n=5) and TG (n=5) animals. (B) Western blot analysis of the same WT and
TG hearts used in A using a polyclonal antibody against ERK2 (inactivated
ERK2).
3.2.3. p38
Finally, Western blot using an antibody against p38, the last big member of the
MAPKs superfamily, was also performed. In hearts of TG and WT mice no
differences were found in the protein levels of phosphorylated (activated) p38
(Fig. 10A). An antibody against the inactivated form of p38 was used and
revealed equal amount of non-phosphorylated proteins in WT and TG hearts (Fig.
10B).
Fig. 10. (A) Western blot analysis of hearts from WT (left) and TG (right) mice
using a polyclonal antibody against phosphorilated-p38. No statistical differences
in the protein levels can be detected between WT (n=5) and TG (n=5) animals. (B)
Western blot analysis of the same WT (left) and TG (right) hearts used in A using
a polyclonal antibody against p38 (inactivated p38).
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3.2.4. TNF-α
It is already known that activated leukocytes are the major source of TNF-α. In
order to check if activated leukocytes, found in the hearts of TG animals (see
3.3.4.), express TNF-α, we performed Western blot analysis using an antibody
against TNF-α. TNF-α expression was significantly (1.8-fold) increased in the
heart of TG mice when compared with WT (Fig.11).
Fig. 11. (A) Western blot analysis of hearts from WT and TG animals, using a
polyclonal antibody against TNF-α. The band at 26 kDa level probably
corresponds to a transmembrane precursor form of TNF-α, the band at 17 kDa
corresponds to the active form of TNF-α. (B) Quantification of TNF-α protein in
WT (n=4) and TG (n=4) hearts. The heart samples used for TNF-α protein level
quantification were the same used for phosphorylated-SAPK/JNK1/2 protein
level quantification by Western blot.
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3.3. Histomorphology, immunohistochemistry, and ultra-
structure
We performed ultrastructural comparative study of neonatal, young, adult, and
old TG mice in order to establish a temporal pattern of MCP-1 overexpression. In
addition, histomorphological examination of hearts from TG and WT mice were
performed to study morphological changes due to MCP-1 overexpression.
3.3.1. One day old TG mice
Using electron microscopic analysis we found that the myocytes of 1 day old TG
mice were normal (Fig. 12A). Isolated monocytes/macrophages and fibroblasts in
the myocardial interstitium were present (Fig. 12B).
Fig. 12. (A) Electronmicrograph of a heart from a 1 day old TG mouse.
Cardiomyocytes show normal ultrastractural appearance of nuclei (N) as well as
mitochondria (Arrows). x3000.
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Fig. 12. (B) Electronmicrograph of a heart from a 1 day old TG animal. TG
myocardium. Isolated monocytes/macrophages (Arrow) and fibroblasts (F) were
found. x3000.
3.3.2. One month old TG mice
Electron microscopic analysis revealed the presence of normal myocytes in the
heart of 1 month old TG mice (Fig. 13A,B). In addition, isolated fibroblasts
(Fig. 13A), lymphocytes (Fig. 13B), and monocytes/macrophages (Fig. 13C) were
found in the myocardial interstitium with increased number when compared with
1 day old TG mice.
3.3.3. Two months old TG mice
The myocardium of 2 months old TG mice exhibits a normal histological
appearance (Fig. 14A). However, calcium accumulation were found in the
cytoplasm of cardiomyocytes,  and small  accumulations of
monocytes/macrophages, fibroblasts and lymphocytes in the ventricular
interstitium were present (Fig. 14B,C).
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Fig. 13. (A) Electronmicrograph of a heart from a 1 month old TG animal.
TG cardiomyocyte nuclei (N) and mitochondria (Arrows) are of normal
ultrastractural appearance. F: fibroblast. x4500.
Fig. 13. (B) Electronmicrograph of a heart from a 1 month old TG mouse. TG
myocardium. N: cardiomyocyte nuclei. L: lymphocyte. x3000.
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Fig. 13. (C) Electronmicrograph of a heart from a 1 month old TG mouse. TG
myocardium. M: monocyte/macrophage. x4500.
Fig. 14. (A) Electronmicrograph of a heart from a 2 months old TG mouse.
Cardiomyocytes show normal ultrastractural appearance of nuclei (N) as well as
mitochondria (Big arrows). Small arrows: Intracellular calcium accumulations.
x2000.
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Fig. 14. (B) Electronmicrograph of a 2 months old TG animal. Myocardial
interstitium showing a small leukocyte accumulation composed of
monocyte/macrophage (M) and fibroblast (F). x3000.
Fig. 14. (C) Electronmicrograph of a heart from a 2 months old TG mouse.
Myocardial interstitium. L: lymphocyte. x7000.
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3.3.4. Adult (3-5 months old) TG mice
The myocardium of WT mice was of normal histological appearance (Fig. 15A),
whereas TG hearts showed large accumulations of infiltrating cells in the
ventricular interstitium, surrounding the vessel walls of both, arteries and veins,
and in the subepicardial space (Fig. 15B,C). Fig. 15B and C show ventricular
sections of a 3-months and a 9-months old mouse, respectively. This picture
clearly shows that the interstitial accumulations increased in number and size
with the age of the animals. The interstitial cells were identified as
monocytes/macrophages, lymphocytes, granulocytes, and fibroblasts (Fig. 15D).
The atrial myocardium of TG mice showed also interstitial cell accumulations but
the cells observed were mainly granulocytes (Fig. 15E).
Fig. 15. H&E staining.
(A) Ventricular myocardium of
a WT heart. x250. (B) Ventri-
cular myocardium of a 3
months old TG mouse.
Arrows: foci of interstitial
cells. x250. (C) Ventricular
myocardium of a 9 months old
TG mouse. Arrows: foci o f
interstitial cells. x250.
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Fig. 15. H&E staining. (D) High magnification of an interstitial cell
accumulation. Big arrow: lymphocyte. Arrowhead: monocyte/macrophage. Small
arrow: fibroblast. x630. (E) Atrial myocardium of a TG heart. Arrows: foci of
granulocytes. x250.
Electron microscopic analysis confirms the presence of monocytes/macrophages,
lymphocytes, and fibroblasts in the myocardial interstitium of TG mice(Fig. 16A).
In addition, electron microscopic analysis showed also the present of activated
monocytes/macrophages as well as activated lymphocytes (Fig. 16B).
CD 71
In order to investigate the state of activation of the infiltrating cells present in
the interstitial accumulations we used an antibody against the transferrin
receptor (CD71), a known marker of activated lymphocytes (Knapp et al. 1989;
Kishimoto et al. 1997). We found that TG animals showed a high proportion of
activated lymphocytes (CD71-positive cells) in both the left and right ventricles,
surrounding the vessel walls and in the subepicardial space (Fig. 17A). In WT
mice, isolated positive interstitial cells were only sporadically detected (Fig. 17B).
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Fig. 16. Electron microscopy. (A) TG heart. Myocardial interstitium. L:
lymphocyte. M: monocyte/macrophage. F: fibroblast. x4500.
Fig. 16. Electron microscopy. (B) TG heart. Myocardial interstitium. M:
activated monocyte/macrophage. x7000.
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TNF-α
In order to check which kind of cells are expressing TNF-α  in the heart of TG
mice, we performed immunohistochemistry using an antibody against TNF-α. In
TG hearts TNF−α immunostaining was detected in cells present in the
myocardial interstitium and the subepicardial space (Fig. 18A). TNF-α immuno-
staining was also found weakly in the media of coronary vessels (not shown).
TNF-α-positive interstitial cells were identified as monocytes/macrophages,
lymphocytes and fibroblasts (Fig. 18B). In WT hearts, weak TNF-α immuno-
staining was also found in the media of coronary vessels, and in the myocardial
interstitium (Fig. 18C).
Fig. 17. Immunofluorescence
for CD 71 (green). (A) TG heart.
The interstitial accumulations are
composed by many CD 71-positive
cells. E: epicardium. V: coronary
vein. x400. (B) WT heart. Positive
cells (arrow) are not frequent in
WT mice. Nuclei are stained red
with propidium iodide. x630.
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Fig. 18. Immonuhistochemistry
for TNF-α. (A) WT heart. TNF-
α staining was found mainly in
the media of coronary vessels
(arrows) and weakly in the
myocardial interstitium. x250.
(B) TG heart. TNF-α staining is
located in the myocardial inter-
stitium and in the supepicardial
space. E: epicardium. x250. (C)
TG heart. High magnification of
leukocyte accumulations showing
TNF-α-positive interstitial cells.
The nuclei were counterstained
with hematoxilin. Big arrow:
monocyte/macrophage,
arrowhead: fibroblast, small
arrow: lymphocyte. x630.
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Fig. 19. Immunohistochemistry for phosphorylated-SAPK/JNK1/2. (A) TG
heart. Distribution of phosphorylated-SAPK/JNK1/2 in the left ventricle. x250.
(B) TG heart. Phosphorylated-SAPK/JNK1/2 staining was found in the nuclei of
myocytes (arrow) and leukocytes (arrowhead). x1000.  (C) WT heart. Distribution
of phosphorylated-SAPK/JNK1/2 in the left ventricular myocardium. x250 (D)
WT heart. Phosphorylated-SAPK/JNK1/2 staining was detected in the nuclei of
myocytes (arrow). x1000. (E) Quantification of the phosphorylated-SAPK/JNK1/2
intensity level in WT and TG mice. The sections used in this figure were stained
and photographed using the same conditions. The difference in the optical density
between TG and WT cardiomyocyte nuclei is evident.
Phosphorylated-SAPK/JNKs
We performed immunohistochemistry using an anti-phosphorylated-
SAPK/JNK1/2 antibody in order to identify the type of cells that express
phosphorylated-SAPK/JNK1/2 in the heart of TG mice. We found phosphorylated
(activated) SAPK/JNK1/2-positive cardiomyocytes as well as SAPK/JNK1/2-
positive infiltrating cells in the hearts of TG mice (Fig. 19A). The phosphorylated-
SAPK/JNK1/2 immunostaining was located around the nuclei as well in the
cytoplasm of MCP-1 cardiomyocytes (Fig. 19A). The WT hearts showed also
phosphorylated-SAPK/JNK1/2-positive cardiomyocytes (Fig. 19C). The phospho-
rylated-SAPK/JNK1/2 immunostaining was found in a perinuclear position but
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not in the cytoplasm (Fig. 19C,D). To exclude the possibility that phosphorylated-
SAPK/JNK1/2 positive leukocytes, detected in TG hearts, could be responsible for
the increased levels of phosphorylated-SAPK/JNK1/2 found in TG animals by
Western blot, we performed intensity quantification of phosphorylated-SAPK/
JNK1/2-positive cardiomyocytes in TG and WT mice. The analysis revealed a
significant increase in the optical density of the staining in TG cardiomyocytes as
compared to WT (Fig. 19B,D,E).
3.3.5. Old (6-10 months old) TG mice
3.3.5.1. Cardiomyocyte injury
The hearts of adult and old TG mice showed damaged cardiomyocytes scattered
throughout the myocardium increasing in number with increasing age of the
animals (Fig. 20A). The damaged myocytes were surrounded by leukocytes as
showed in Fig. 20A. Using electron microscopic analysis it was possible to
demonstrate that the damaged cardiomyocytes containing damaged mitochondria
appeared to be necrotic (Fig. 20B). In addition, the ultrastructural analysis
showed that necrotic myocytes in the heart of TG mice were usually accompanied
by leukocytes (Fig. 20B).
3.3.5.2.Cell death
In order to study the occurrence of different types of injury leading to cell death
in MCP-1-overexpressing-cardiomyocytes, we investigated cardiomyocyte damage
by ischemic injury using an antibody against complement 9, by autophagy using
an antibody against ubiquitin, and antigen presentation using an antibody
against MHC II.
Ubiquitin
In WT hearts ubiquitin-positive cardiomyocytes were only sporadically detected.
Ubiquitin depositions were found in the nuclei of WT cardiomyocytes (Fig. 21A).
The heart of TG mice showed accumulation of ubiquitin in the cytoplasm and in
the nuclei in a high proportion of myocytes. In fact, 64‰ of the total number of
myocytes were found ubiquitin-positive (Fig. 21B,C). In MCP-1 cardiomyocytes,
ubiquitin exhibited different degrees of depositions (accumulations) including
spots and very large and intense accumulations (Fig. 21B,C). For quantification
we counted only perinuclear and cytoplasmic ubiquitin accumulations as shown
in Fig. 21B,C excluding nuclear ubiquitin accumulations.
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Fig. 20. Nine months old TG mouse. (A) H&E staining. TG heart. Damaged
cardiomyocytes (arrows) are surrounded by leukocytes (arrowheads). x630.
(B) Electron microscopy. TG heart. A lymphocyte (L) appears located within a
necrotic myocyte exhibiting damaged mitochondria (arrows). x1000.
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Fig. 21. Immunofluorescence for
ubiquitin antibody (green). Cardio-
myocytes are stained in red with
phalloidin. Nuclei are stained in
blue with DAPI. (A) WT heart.
Depositions of ubiquitin were
accasionally detected only in the
nuclei of myocytes. (B) and (C) TG
hearts. Different degree of ubiquitin
accumulations are present in TG
cardiomyocytes.
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Complement 9
Using an antibody against complement 9, a known marker of acutely ischemic
necrotic cells, it was possible to quantify the total amount of necrotic
cardiomyocytes observed by conventional histology and ultrastructural analysis
in TG animals (Fig.22A). We found that 3‰ of the total number of myocytes were
complement 9-positive in TG hearts (Fig. 22A), while WT hearts showed no
complement 9-positive-myocytes (Fig. 22B).
Fig. 22. Immunfluorescence for
complement 9 antibody (green).
Cardiomyocytes are stained in red
with phalloidin. Nuclei are
stained in blue with DAPI. (A) TG
heart. Complement 9-positive-
cardiomyocyte (green). Note the
lack of phalloidin staining in the
complement 9-positive myocyte
indicating irreversible necrosis.
(B) WT heart. Complement 9-
positive cells are not present.
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MHC II
Using an antibody against MHC II, no MHC II-positive- cardiomyocytes were
found in the WT hearts (Fig. 23A) while TG cardiomyocyte were found positive
for MHC II as shown in Fig. 22B. The MHC immunostaining was found in the
myocyte cell membrane of 3‰ of total number of TG myocytes (Fig. 23B,C).
Fig. 23. Immunofluorescence for
MHC II antibody (green). Cardio-
myocytes are stained in red with
phalloidin. Nuclei are stained in
blue with DAPI. (A) WT heart.
MHC II-positive myocytes were not
detected. (B) TG heart. MHC II-
positive cardiomyocytes (green)
were detected in TG ventricles.
Note that this MHC II-positive
cardiomyocyte is the same showed
in Fig. 22, which is positive for
complement 9.
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Apoptosis
The programmed cell death, apoptosis was checked in TG and WT animals in
order to complete the study regarding MCP-1-overexpression-induced cell death.
In addition, we wanted to investigate the possibility that activation of
SAPK/JNK1/2 might cause apoptosis in the heart of TG mice. We used an
apoptosis detection system. TUNEL-positive cardiomyocytes were detected
neither in TG nor in WT animals (Fig. 24A,B). In the heart of TG mice, TUNEL-
positive interstitial cells were found (Fig. 24B). In the duodenum, used as
positive control, many TUNEL-positive cells were found (Fig. 24C).
Fig. 24. TUNEL staining
(red). (A) TG heart. No TUNEL-
positive myocytes were present.
TUNEL-positive infiltrating cells
(red) were occasionally detected.
(B) WT heart. TUNEL-positive
cardiomyocytes were not present.
(C) Duodenum of pig used as
positive control. Many TUNEL-
positive cells (red) were present.
Green: phalloidin. Blue: DAPI.
Yellowspots:lipofuscin.
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4. Discussion
4.1. Cardioprotection
Our results indicate that MCP-1 overexpression exerts myocardial protection
against short-term (45 min) vs longer term (3 days) of ischemia. In addition,
these studies show that after short-term ischemia followed by 3 days of
reperfusion the infarct size was still reduced in TG mice when compared with WT
but it was increased when compared with 45-min of coronary artery occlusion
demonstrating that some of the salvaged myocardium died during reperfusion
but another part was rescued by reperfusion. This cardioprotection is not caused
by angiogenic or arteriogenetic mechanisms because infarct size was similar in
TG and WT mice after long-term (3 days) CAO. We can conclude that MCP-1
overexpression induces a permanent reduction in infarct size by a short-acting
mechanism that mimics ischemic preconditioning.
The results presented here indicate an important role for the MAPK family in
mediating the cardioprotective effect. Evidence for the activation of different
MAKs subfamilies during ischemic preconditioning has been reported by
different autors (Maulik, Watanabe et al. 1996; Weinbrenner, Liu et al. 1997;
Barancik, Htun et al. 1999; Baines, Cohen et al. 1999; Nakano, Baines et al.
2000; Sato, Cordis et al. 2000; Saurin, Martin et al. 2000). Although many of
these studied suggested MAPKs importance as signaling components in the
protection of the myocardium achieved by ischemic preconditioning against
ischemia (Maulik, Watanabe et al. 1996; Weinbrenner, Liu et al. 1997; Maulik,
Yoshida et al. 1998; Yue, Ma et al. 1998; Barancik, Htun et al. 1999; Baines,
Cohen et al. 1999; Nakano, Baines et al. 2000; Sato, Cordis et al. 2000; Strohm,
Barancik et al. 2000), others supposed a deleterious effects of MAPKs activation
during ischemic preconditioning (He, Li et al. 1999; Saurin, Martin et al. 2000).
Moreover, in the last years, the available of specific inhibitors of MAPKs have
permitted the study of the role of each MAPKs in ischemic preconditioning as
well as the signaling transduction pathways downstream of each MAPK (Murray,
Alessandro et al. 1998; Yue, Ma et al. 1998; Barancik, Htun et al. 1999; Strohm,
Barancik et al. 2000; Sato, Cordis et al. 2000; Yue, Wang et al. 2000). However,
the exact role of each member of the MAPKs superfamily is still controversial
and under discussion. It has been demonstrated in different organs and animal
models that the ERKs pathway is correlated with the induction of survival,
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having a protection effect against apoptosis (and in general cell death) both in
vitro and in vivo (Xia, Dickens et al. 1995; Gu, Jiang et al. 2000; Henaff, Hatem
et al. 2000; Strohm, Barancik et al. 2000). In vitro, inhibition of the ERKs
transduction pathway with specific inhibitors increased apoptosis in cultured
cardiac myocytes in an ischemic-reoxygenation-induced apoptosis rat model (Yue,
Wang et al. 2000), as well as exaggerated reperfusion injury in isolated perfused
rat heart (Yue, Wang et al. 2000). In vivo, inhibition of the ERKs pathway results
in an increased infarct size in a pig model of coronary artery occlusion (Strohm,
Barancik et al. 2000). Although the activation of the ERKs pathway plays an
important role in preventing stress-induced apoptosis in cardiac myocytes, in a
cell culture model of seizure activity it has been reported that inhibition of the
ERKs pathway protects hippocampal neurons suggesting a role of ERKs
activation in the induction of cell death (Murray, Alessandro et al. 1998).
The activation of the p38 pathway is in general correlated with the induction of
apoptosis and with stress responses (Yue, Wang et al. 2000; Bogoyevitch,
Gillespie-Brown et al. 1996; Saurin, Martin et al. 2000; Kyriakis and Avruch
2001). Inhibition of the p38 cascade protects cultured myocytes against apoptosis
in an ischemia/reoxygenation-induced apoptosis rat model (Yue, Wang et al.
2000) but also increases myocardial infarction in an isolated rat heart model of
ischemic preconditioning followed by ischemia/reperfusion (Sato, Cordis et al.
2000), suggesting that activation of the p38 signal transduction pathway is an
important (and maybe necessary) component in the ischemic preconditioning
program (Nakano, Baines et al. 2000).
The activation of the SAPK/JNKs pathway was originally associated with the
induction of cell death (He, Li et al. 1999; Lin, Weinberg et al. 2000; Yue, Wang
et al. 2000). In vitro, activation of the SAPK/JNKs pathway occurs at the onset of
apoptosis and inhibition of this pathway reduces hypoxia-induced apoptosis in
cultured myocytes (He, Li et al. 1999; Lin, Weinberg et al. 2000; Baines, Cohen et
al. 1999). In vivo, inhibition of SAPK/JNKs activation reduces reperfusion injury
in perfused rabbit hearts (Yue, Ma et al. 1998) and protects hippocampal neurons
against ischemia-induced apoptosis (Ozawa, Shioda et al. 1999). However, in
marked contrast, recent studies have demonstrated that SAPK/JNKs activation
exhibits a cytoprotective effect in nitric oxide-induced cardiac myocyte apoptosis
(Andreka, Zang et al. 2001). Sato et al. (Sato, Cordis et al. 2000) reported that
activation of the SAPK/JNKs pathway is obligatory for ischemic preconditioning
in isolated rabbit hearts. In addition, stimulation of SAPK/JNK1/2 with okadaic
acid and anisomycin reduced infarct size in a pig model of coronary artery
occlusion (Barancik, Htun et al. 1999). Despite the confusion generated by the
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controversial data regarding the role of MAPKs, it is now recognized that the
functions of the MAPKs subfamilies can vary, and even oppose each other
depending on the cell type, stimuli, and model system used. In addition, it is
likely to suppose that in ischemic preconditioning and/or ischemia/reperfusion,
the dynamic balance between MAPKs activity and the presence of specific
signaling transduction-activating co-stimuli are crucial and critical in
determining cardiomyocyte survival or death subsequent to injurious
stimulation.
Our data show a permanent activation of the SAPK/JNK1/2 pathway in MCP-1
TG hearts. In addition, we reported that injection of the SAPK/JNKs inhibitor D-
JNKI1 partially abrogates the cardioprotective effect of MCP-1 overexpression,
leading to a significantly increased infarct size in treated TG mice versus
untreated TG animals. In addition, the other two mayor MAPKs subfamilies,
ERK1/2 and p38, are not activated in MCP-1 TG hearts, suggesting that, in our
transgenic model, ERK1/2 and p38 signaling transduction pathways do not
contribute to the cardioprotective effect observed in MCP-1 TG mice. We
hypothesize that the permanent activation of SAPK/JNK1/2 in MCP-1 TG hearts
could lead in TG cardiomyocytes to a preconditioned state that increases myocyte
survival (with consequent infarct size reduction) after simulated ischemia. Our
hypothesis is supported by data obtained with the use of the SAPK/JNKs
inhibitor D-JNKI1. We can conclude that a permanent activation of the
SAPK/JNKs signal tranduction pathway in MCP-1 TG mice is in part involved in
the development of cardiac resistance against ischemia.
Very recently, Smith et al. (Smith, Lecour et al. 2002) have proposed innate
immunity as an integral component of the “innate adaptive cardiac program”
(ischemic preconditioning) that leads to cardiac protection after ischemic injury
(Smith, Lecour et al. 2002). This cytoprotective program appears to be mediated
by pro-inflammatory cytokines, in which TNF-α,  an apical cytokine in the
immune system, has been proposed to play an important and beneficial role.
TNF-α is produced during viral myocarditis (Matsumori, Yamada et al. 1994) and
ischemia/reperfusion (Gurevitch, Frolkis et al. 1996; Frangogiannis, Lindsey et
al. 1998; Kupatt, Habazettl et al. 1999), both charaterized by inflammatory
processes development. The production of TNF-α  was generally considered
deleterious to the cardiovascular system. Administration of TNF-α  aggravates
myocarditis in a mouse model of myocarditis induced by encephalomyocarditis
virus (Yamada, Matsumori et al. 1993). Neutralization of TNF-α  with specific
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antibodies has been reported to ameliorate viral and autoimmune myocarditis
(Yamada, Matsumori et al. 1993; Smith and Allen 1992), and to improve
myocardial recovery after ischemia/reperfusion (Gurevitch, Frolkis et al. 1997).
Systemic administration of this cytokine results in myocardial depression and
cardiomyopathy (Bozkurt, Kribbs et al. 1998; Hegewish, Weh et al. 1990; Kubota,
McTiernan et al. 1997). In marked contrast, it is now being recognized that
TNF-α production is not merely linked to detrimental effects but that it can have
a protective action after both, viral myocarditis and myocardial infarction
(Kurrelmeyer, Michael et al. 2000; Wada, Saito et al. 2001; Lecour, Minners et al.
1999; Smith, Suleman et al. 2002; Sack, Smith et al. 2000; Mann 2001). In fact,
Wada et al. (Wada, Saito et al. 2001) demonstrated using mice lacking
TNF-α that this cytokine plays a protective role during acute myocarditis because
is necessary for adhesion molecule expression and leukocyte infiltration. A
protective effect of TNF-α  against apoptosis after coronary occlusion has been
shown in mice lacking both TNFR1 and TNFR2 (Kurrelmeyer, Michael et al.
2000). Moreover, recently Smith RM et al. (Smith, Suleman et al. 2002)
demonstrated that cardiac production of TNF-α  is required for ischemic-
preconditioning-induced cardioprotection.
TNF-α  can activate the SAPK/JNKs signaling transduction pathway (Darnay
and Aggarwal 1997), and the binding of TNF-α with its receptors can lead to an
apoptotic or a survival signaling cascade, both through SAPK/JNKs activation
(Darnay and Aggarwal 1997). In fact, new evidence demonstrated that TNFRs
might be coupled to activation of different downstream transduction pathways,
depending on the association of the receptors with adapter proteins. This is due
to the ability of the TNFRs to associate with specific intracellular proteins:
TRAFs and FADD/MORTs. These proteins can induce selective activation of
SAPK/JNKs leading to the survival or death signaling cascade through MEKK1
or Caspase-8 activation, respectively (Darnay and Aggarwal 1997; see also Fig.
3). Roulston et al. (Roulston, Reinhard et al. 1998) showed that after the binding
of TNF-α with the receptors  there is an early and transient activation of
SAPK/JNKs, NF-kB, and p38 mediated through TRAF2, which is directly bound
to TNFR2, and via TRADD to TNFR1. These authors propose that these
signaling cascades may coordinate protective signals, preventing apoptosis and
cell injury. If one of the protective signals is inhibited or specific pro-apoptotic
stimuli are present, the apoptotic pathway will proceed, via FADD that is bound
to TRADD, leading to the activation of a cascade of Caspases, which then result
in late phase stress kinase activation and apoptosis (see Fig. 3). In MCP-1 TG
hearts we found incresead level of TNF-α . Immunohistochemical analysis
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revealed that leukocytes and fibroblasts accumulating in the myocardial
interstitium of TG hearts are the source of TNF-α. We suggest that activated
leukocytes secreting TNF-α  serve as stimulus for the activation of the
SAPK/JNK1/2 signaling transduction pathway in TG cardiomyocytes. In our
model, the Caspase-8-independent pathway seems to be responsible for
SAPK/JNKs activation leading to cell survival and not to apotosis. This is also
confirmed by the fact that in TG hearts neither apoptotic TUNEL-positive
cardiomyocytes nor activation of the pro-apoptotic factor p38 could be observed. It
is likely that in our TG model the production of TNF-α plays a beneficial role in
the induction of cardiac protection against short-term ischemia, possibly
activating a signaling cascade down-stream of TNFR leading to cytoprotective
and not to cell death programs. Our data may be further evidence for the
beneficial link proposed by Smith et al. (Smith, Lecour et al. 2002) between the
immune system and ischemic preconditioning. Moreover, we propose that the
link existing between innate immunity and ischemic preconditioning could act
trough SAPK/JNKs activation.
4.2. Cardiomyopathy
The MCP-1 TG mice have a very short life span (~10 months against ~18 months
in WT mice) due to the development of inflammatory cardiomyopathy and
pulmonary edema, which start approximately at 3-4 months after birth and
increase until the death of the animal (Kolattukudy, Quach et al. 1998; Martire,
Fernandez et al. 2001; Moldovan, Goldschmidt-Clermont et al. 2001).
Kollatukudy et al. (Kolattukudy, Quach et al. 1998) described the development of
cardiomyopathy in MCP-1 TG mice from neonatal to 2 months old. In TG hearts,
MCP-1 overexpression starts before birth and increases until ~2 months of age
where it remains constant until the death of the animal. At this early age the
mice show infiltration of only monocytes/macrophages in the myocardial
interstitium. They also show that the monocytes/macrophages were not
activated.
Although it is established that in vitro MCP-1 is a chemoattractant for
monocyte/macrophages and lymphocytes (Gunn, Nelken et al. 1997; Sekine,
Yasufuku et al. 2000), the development of a variety of TG and deficient mice
models indicate that MCP-1 has similar properties in vivo. In fact, TG mice
overexpressing MCP-1 in a variety of organs showed a moderate number of
monocytes/macrophages (and in the same animal model also lymphocytes)
infiltrations and accumulations at the sites of MCP-1 overexpression (Gunn,
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Nelken et al. 1997; Fuentes, Durham et al. 1995; Kolattukudy, Quach et al.
1998). Interestingly, other TG mice that also overexpress MCP-1 in a variety of
organs showed any monocytes/macrophages infiltration at the sites of
overexpression (Roulston, Reinhard et al. 1998).
In vitro, MCP-1 has been shown to activate monocytes as well as lymphocytes
(Jiang, Beller et al. 1992; Lukacs, Chensue et al. 1997; Gavrilin, Deucher et al.
2000) but it is unclear whether MCP-1 in vivo may activate these cells (Jiang,
Beller et al. 1992; Lukacs, Chensue et al. 1997; Gavrilin, Deucher et al. 2000). In
fact, in all the transgenic model studies, MCP-1 alone does not induce activation
of attracted cells but in some cases it can enhance the inflammatory response
when treated with other pro-inflammatory stimuli (Gunn, Nelken et al. 1997). In
general, the relatively benign appearance of monocytes/macrophages attracted in
vivo in response to transgenically production of MCP-1 demonstrates that the
degree (and organs) of overexpression maybe somewhat limited. The same
applies to leukocyte activation. There is a variety of monocyte activation states,
and maybe in these TG mice models MCP-1 does not activate monocytes to a
degree sufficient to stimulate them to differentiate into macrophages and to
express adhesion molecules and cytokines but enough to induce in same cases a
moderate inflammatory process (Kolattukudy, Quach et al. 1998), as well as to
enhance inflammatory responses when stimulated with other pro-inflammatory
stimuli (Gunn, Nelken et al. 1997).
The MCP-1 TG mice described in the present study are young (1 day, 1 month, 2
months), adults (3-5 months old), and old (6-10 months old). Our results confirm
the finding of Kollatukudy et al., which showed moderate infiltration of
monocytes/macrophages leading to moderate autoimmune myocarditis in the
heart of young TG mice. In addition, the present results indicate that, in adult
TG mice, lymphocytes, together with monocytes/macrophages and fibroblasts,
constitute the principal cell types in the ventricular interstitial cell
accumulations. Moreover, we showed that an important fraction of the leukocytes
were also activated in MCP-1 TG hearts. The present results provide in vivo
evidence for the capacity of MCP-1 not only for attracting
monocytes/macrophages and lymphcytes but also for its capacity to induce their
activation. However, we cannot exclude that the moderate autoimmune
myocarditis detected in MCP-1 TG mice may additionally induce attraction and
activation of lymphocytes. In this case, chemotaxis and activation of lymphocytes
would not be a direct effect of MCP-1 overexpression, but secondary to
cardiomyocyte degeneration (see below).
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 Moldovan et al. (Moldovan, Goldschmidt-Clermont et al. 2001)  showed necrotic
cardiomyocytes in old MCP-1 TG mice. These authors described the presence of
necrotic myocytes as a consequence of the occlusion of small arteries and
arterioles found in TG hearts, which generates diffuse ischemic regions
(Moldovan, Goldschmidt-Clermont et al. 2001). Occlusion of small arteries and
arterioles should induce foci of necrotic myocytes at the site of coronary blood
flow arrest. We found also necrotic cardiomyocytes in old MCP-1 TG mice (6-9
months old), but they were isolated. We suggest that the presence of necrotic
cardiomyocytes is likely due to the general autoimmune inflammation described
in TG hearts and not to ischemic injury. In fact, although we have not performed
statistical analysis for colocalization of complement 9 and MHC II antibodies, we
found complement 9- and MHC II-positive cardiomyocytes scattered through the
myocardium in TG hearts (compare Fig. 22 with Fig. 23), suggesting that
complement cascade activation is induded at least in part by the MHC II
presentation in the cell membrane of cardiomyocytes (see belove). However, we
cannot exclude that transgenic manipulation and prolonged protein
overexpression could also induce cardiomyocyte degeneration (see below).
The ubiquitin system of intracellular proteolysis has been shown to be essential
for cell viability (Weissman 2001). In fact, embryonic development and cell death,
which are characterized by large intracellular reorganization and degradation of
internal organelles and proteins, have been shown to activate the ubiquitin
system, which leads to protein-ubiquitination of target proteins (Mayer, Arnold et
al. 1991; Doherty, Laszio et al. 1989; Lowe and Mayer 1990). It has been
described that in different pathological situations such as neurodegenerative,
viral or other chronic degenerative diseases, ubiquitin is abnormally accumulated
in nuclei or cytoplasm and functions are altered (Mayer, Arnold et al. 1991;
Layfield, Alban et al. 2001). It has been proposed that ubiquitin deposits in
degenerative and viral diseases are cellular responses to stress, damage and
injury (Layfield, Alban et al. 2001). In neurodegenerative diseases, characterized
by an abnormal production of damaged neuronal proteins or organelles,
accumulation of ubiquitin has been proposed to have two opposite functions.
Protein ubiquitination might cause neuron death as part of an irreversible
pathological process or cytoprotection trying to rescue neurons as a part of
reversible pathological processes (Mayer, Arnold et al. 1991). The other
possibility proposed by the same authors is that protein ubiquitination starts as a
cytoprotective process. When the process cannot combat neuronal degeneration
or the degree of injury is too much, protein ubiquitination is involved in
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destroying neuron proteins in the final stage of cell death (Mayer, Arnold et al.
1991). In fact, there are evidences suggesting that in neurodegeneration the
cytoprotective role of protein ubiquitination in neurons probably occurs only at
preterminal stages of diseases progression (Mayer, Arnold et al. 1991; Lowe and
Mayer 1990).
In our model, the altered accumulations of ubiquitin found in the cytoplasm of
TG cardiomyocytes could have also two opposite functions: cytoprotection or
induction of cell death. In fact, cellular stress induced by transgenic production of
MCP-1 by myocytes and its abnormal intracellular accumulation in cells could
induce protein-ubiquitination for initiating the degradative process of
uncontrolled MCP-1 protein accumulation. The degradative process could take
place for both, rescue the myocytes from high and toxic levels of MCP-1 and when
its production raises letal levels, for destroying irreversible damaged myocytes in
the final stage of cell death. We propose that the degree of MCP-1 accumulation
is important for establishing if the cell will be rescued or not. Our hypothesis is
supported by the fact that immunofluorescence using an antibody against MCP-1
revealed that in MCP-1 TG hearts the degree of MCP-1 accumulated in the cells
varies from myocyte to myocyte in the same animal (data not shown). MCP-1
accumulated in the myocytes could induce MCP-1-ubiquitination in order to
rescue the myocytes from an abnormal and possibly toxic protein deposition in
the cytoplasm. In our model could also occurs that when the cytoprotective
program could not take place due to the large amount of MCP-1 accumulated in
the cell, the MCP-1-ubiquitination could also induce the destruction and the
death of TG cardiomyocytes. Immunohistochemical analysis performing
colocalization of MCP-1 and ubiquitin antibodies could confirm our hypothesis.
Activation of the complement system has been shown to play an important role in
the induction of humoral immune responses, in the elimination of immune
complexes, in the protection against bacterial and viral infections, and in general
in autoimmune and inflammatory responses. Two mechanisms are known to be
capable of initiating activation of the classic complement pathway: an antibody-
dependent mechanism in which specific immunoglobulins bind antigen and that
complex leads to complement activation (Porter and Reid 1979), and an antibody-
independent mechanism in which cytosolic particles leaking from necrotic cells
react with different members of the complement system without requiring
antibody-antigen complex formation, which then activates the complement
system (Pinckard, Olson et al. 1975; Linder, Lehto et al. 1979). The antibody-
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dependent mechanism is the best characterized. It has been demonstrated that in
injuries, in which a rapid activation of the complement system occurs via
antibody-dependent mechanisms, novel antigenic determinants are presented to
pre-existing immunoglobulins, because the activation occurs too rapidly to permit
the production of new immunoglobulins for an unknown antigen (Kelley, Olson et
al. 1974).
The antibody-independent mechanism of complement system activation is still
poorly understood (Giclas, Pinckard et al. 1979). However, complement 9 mRNA
has been shown to be upregulated under stress characterized by an inflammatory
reaction (Yasojima, Kilgore et al. 1998) and in general in models of muscle injury,
including myocardial ischemia and ischemia/reperfusion injury (Giclas, Pinckard
et al. 1979). In fact, in ischemia/reperfusion injury, mitochondrial proteins
leaking from the injured cardiac cells could directly or indirectly cause the
activation of complement without requiring antibody binding. In the present
study, we showed necrotic complement 9-positive cardiomyocytes by
immunofluorescence as well irreversible damaged cardiomyocytes by
conventional microscopy. We suggest that the general autoimmune
inflammation, detected in adult and old MCP-1 TG mice, induces cardiomyocyte
damage and death. The loss of membrane integrity that occurs in irreversible
damage could expose cytoplasmic molecules to the circulating members of the
complement system, which in turn could induce the complement cascade
activation. We suggest that the complement system attacks necrotic TG
cardiomyocyte membranes with consequent activation of the complement cascade
that leads to the removal of the irreversible damaged (necrotic) cardiomycytes.
The exposure of MHC II antigens in the cell surface induces tissue-specific
immune destruction by lymphocytes (Klein 1990). Cells that expose MHC II
molecules in the cell membrane are target cells for cytotoxic T lymphocytes-
mediated lysis (Klein 1990). An important characteristic of the immune and
autoimmune diseases is their association with MHC II antigens-presenting cells.
It has been shown that cardiac myocytes do not express MHC II antigen on their
surface under normal conditions (Klein 1990) but under pathological conditions,
characterized by activation of the immune system, myocytes express MHC II
antigen and they are susceptible to cytotoxic effects of the immune system
(Caforio, Stewart et al. 1990; Sell, Tadros et al. 1988). In immune diseases
cytotoxic activation of lymphocytes can be induced by viral infection or rejection
after heart transplantation (Sell, Tadros et al. 1988), while autoimmune diseases
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(chronic myocardial damage in the absence of competent infections) are
characterized by the action of autoreactive lymphocytes (Caforio, Stewart et al.
1990). In both cases, activated cytotoxic lymphocytes induce MHC II expression
in the cell membrane of target cells. In MCP-1 TG mice, competent infections
capable of inducing cytotoxic activation of lymphocytes were detected neither in
previously studies (Kolattukudy, Quach et al. 1998; Moldovan, Goldschmidt-
Clermont et al. 2001) nor in the present study. The presence of MHC II antigens
on the cell surface of MCP-1 cardiomyocytes may indicate an autoimmune
inflammatory response of myocytes induced by autoreactive and cytotoxic
activated lymphocytes already described in TG hearts. As mentioned above,
autoimmune diseases are also characterized by complement system activation
(Giclas, Pinckard et al. 1979). In TG hearts, we found colocalization of
complement 9 and MHC II antibodies in cardiomyocytes. It is likely to suppose
that the exposure of MHC II in the cell membrane of TG cardiomyocytes could
induce the complement cascade activation for eliminating damage myocytes. This
could be an evidence for a direct association between MHC II antigen
presentation and complement activation in autoimmune inflammatory diseases.
Further analysis performing quantification of complement 9 and MHC II
colocalization could demonstrate if there is a significant association between
them. Another possibility exists to explain the presence of MHC II in the cell
membrane of TG cardiomyocytes. In fact, the expression of MHC II in cells has
been shown to be regulated by elements in the upstream (promoter) region of
each gene and in the first intron (Klein 1990; Johnson and Pober 1991; Jacob,
Lewis et al. 1991). It has been shown that the genes for both human and mouse
TNF-α and TNF-β are closely linked and located within the MHCs (Spies T et al.
1986), and they can regulate the MHCs expression (Spies, Morton et al. 1986).
TNF-α increases the cell surface expression of MHC I (Collins, Lapierre et al.
1986). MHC II regulation by TNF-α is controversial, probably because of the
different cell types in which it has been studies but in general an increase in the
expression of MHC II antigens in the cell surface by TNF-α has been shown to
occur with additional inflammatory stimuli (Johnson and Pober 1991). We cannot
exclude that in our model the increased levels of TNF-α  (and possibly others pro-
inflammatory cytokines) found in the heart of TG mice could induce activation of
SAPK/JNK1/2 pathway as well as induction of MHC II antigen presentation in
TG cardiomyocytes. On the other hand, MHC II preferentially bind peptides from
exogenous proteins (Klein 1990). For this reason it is likely to suppose that the
overexpression of MCP-1 by myocytes can raise high and toxic levels to induce
myocytes to express MHC II antigens (together with exogenous MCP-1 antigen)
in their surface for eliminating damaged cardiomyocytes.
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In summary, neonatal MCP-1 TG mice (1 day old) show moderate infiltration of
monocytes/macrophages in the ventricular myocardial interstitium but neither
accumulations nor activation of any type of leukocytes could be detected at this
age. One month old MCP-1 TG mice exhibit increased number of mono-
cytes/macrophages when compared with 1 day old animals. Small accumulations
composed by monocytes/macrophages, lymphocytes, and fibroblasts were present
in the myocardial interstitium. Two months old TG mice show mono-
cyte/macrophage, lymphocyte, and fibroblast accumulations that are increased in
size and number as compared with 1 month old mice.
In adult animals (3-6 months old), overexpression of MCP-1 by cardiomyocytes
causes chronic infiltration and activation of leukocytes, resulting in permanent
elevated TNF−α secretion, which could induce activation of SAPK/JNK1/2
pathway. We also showed in adult TG mice that infarct size is permanently
reduced after short-term coronary occlusion, suggesting a cardioprotective role of
MCP-1 overexpression. The permanent activation of SAPK/JNKs pathway
induced by TNF-α production in TG mice could be responsible for the
preconditioning effect of MCP-1 overexpression, inducing activation of
downstream protective (survival and not apoptotic) signaling transduction
pathways in TG cardiomyocytes. The activation of survival pathways could
induce resistance against infarction in TG mice, mimicking ischemic
preconditioning. The data presented using adult TG mice strongly support the
hypothesis proposed by Smith et al. (Smith, Lecour et al. 2002), that exists a
beneficial link between ischemic preconditioning and innate immunity and that
this could take place through (at least) SAPK/JNKs activation.
Old animals (6-10 months) show large accumulations of leukocytes leading to
severe myocarditis, inflammatory cardiomyopathy, edema, and premature death.
Recently, Mann (Mann 2001) has proposed the hypothesis that an appropriate
and moderate production (or administration) of cytokines has beneficial effects
whereas an excessive and prolonged synthesis (or administration) has
detrimental actions. The data presented in the present study strongly support
this hypothesis. In fact, the morphological comparative studies of neonatal,
young, adult, and old mice support the hypothesis that a moderate and
appropriate cytokine production (moderate inflammation observed in adult TG
mice) has beneficial effects (cardioprotection in adult mice). In old animals the
prolonged and excessive synthesis of cytokines (and MCP-1) has detrimental
effects showing the old MCP-1 TG mice myocarditis, cardiomyopathy, different
types of cardiomyocyte injury and death, and premature death.
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